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CHAPTER 1 
1.1 General Introduction 
Ophthalmic melanomas can be divided in extra-ocular (conjunctiva, caruncle) and intra-
ocular uveal melanomas (iris, ciliary body and choroid). Uveal melanomas account for 
95% of ocular melanomas, while only 5% are conjunctival in origin. The extra-ocular and 
intra-ocular melanomas differ in biological behavior. Melanocytes originate from the neural 
crest and are normally present in the uveal stroma, similar to dermal melanocytes. Intra-
epithelial precursor lesions of invasive melanoma occur in the conjunctiva and the caruncle 
but within the eye an intra-epithelial (retinal pigment epithelium) precursor lesion has not 
betH demonstrated. Therefore a radial and vertical growth phase, as is recognized in 
cutaneOUI> and conjunctival melanomas, is not evident in intra-ocular melanoma. Because 
uveal melanomas are not easily accessible for incisional biopsy (without disruption of 
vision), only two lesions of melanocytic origin are defined clinically: nevus and 
melanoma. 1 Progression in melanoma is clinically associated with tumor size. Most 
malignant melanomas of the choroid can be diagnosed by ophthalmoscopy and 
ultrasonography, and evidence of growth is best established by serial photography of the 
fundus. The uvea consists of highly vascularized tissue. There are no demonstrated 
lymphatics within the uveal tract, or in the posterior orbit. This explains the difference in 
biological behavior of ophthalmic melanomas: conjunctival melanomas spread first to 
regional lymph nodes whereas choroidal and ciliary body melanomas metastasize 
hematogenously and preferentially first to the liver. Strikingly, another intra-ocular tumor, 
the retinoblastoma usually does not metastasize until after it has invaded the orbit. From 
the orbit it gains access to lymphatic vessels in the anterior orbit. Unlike uveal melanoma, 
the initial metastases from retinoblastoma are often to regional lymph nodes. Uveal 
melanoma metastasize relatively late: the 5, 10 and 15-year survival rates based on tumor-
related deaths vary from 65%, 52% and 46%, respectively;'" to 72%, 59% and 53%, 
respectively, in recent series.4,5,6 The estimated 5-year-survival rate of cutaneous melanoma 
varies between 70_80%.7.8 Once the diagnosis of hepatic metastasis from uveal melanoma 
has clinically been made) the median survival is extremely poor: between two 9,10 and seven 
months, II The median survival time in patients in whom the liver was either not involved at 
all, or not among the first sites of dissemination is 19 months." 
The question remains how a (histologically) malignant melanoma acquires metastatic 
capacities and seeds malignant cells preferentially to some organs. Organ-specific 
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colonization by malignant cells often follows very specific interactions between the cancer 
cell and the target organ, either in terms of specific cellular adhesion or growth 
promotion.i2,13,14 A metastasizing cell must break loose from its parent tumor, invade the 
matrix between cells and penetrate the wall of a blood vessel. It must pass through the 
blood stream, escape the immune system and emerge from the bloodstream at a favorable 
spot, lodge and induce growth of new blood vessel growth. However, the molecular 
differences between metastasizing and non-metastasizing uveal melanoma cells are not well 
known. The products of oncogenes also play a role in the metastatic competence of a 
tumor. Proto-oncogenes are normal genes that, when activated by mutation or 
translocation, are called oncogenes which contribute to tumorigenesis. It is still not known 
to what extent or in what way oncogenes control the acquisition of cancerous properties or 
if they control the manifestation of metastasis. " 
1.2 Aim of the Thesis 
This thesis deals with melanoma of the posterior uveal tract (choroid and ciliary body); in 
particular with progression of melanomas, defined as the acquisition of irreversible changes 
in the tumor, gaining metastatic potential. For patients with uveal melanoma there is no 
effective therapy once metastases have developed. Survival time for treated, but possibly 
uncured patients is related to the rapidity of the metastatic process. In order to lower 
melanoma-related mortality, it is essential to prevent or eradicate metastatic disease. This 
calls for early detection and for the development of reliable prognostic factors. When an 
effective systemic treatment for metastatic uveal melanoma would be available, early 
administration as an adjuvant to primary treatment may provide the best strategy for control 
of systemic spread. It is therefore necessary to increase our knowledge of the mechanisms 
underlying metastasis, and the identification of reliable progression parameters as 
prognostic markers in primary uveal melanoma. 
Our studies, described in this thesis, have focused on the clinicopathological characteristics 
and the possible role of the products of oncogenes in progression of uveal melanoma. In 
chapter 2 current knowledge on the epidemiology, histology, conventional prognostic 
factors, classification and grading, and survival of human uveal melanoma is summarized. 
The uncommon, relatively benign iris melanoma is shortly described in 2.2. In contrast, 
posterior (choroidal and ciliary body) melanomas have a relatively poor prognosis. The 
clinical symptomatology, growth patterns and indications for aspiration biopsies of these 
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tumors are described in 2.3. In chapter 3 the relevant literature on research on prognostic 
factors in uveal melanoma is reviewed. In chapter 4 a rare precursor of uveal melanoma, 
i.e. atypical melanocytic hyperplasia developing into low grade malignant melanoma is 
described. To investigate the possible UV mediated N-ras oncogene activation, uveal 
melanomas were analyzed for N-ras point mutations (chapter 5). Pre-enucleation 
radiotherapy has been introduced to lower the risk of hematogenous seeding during the 
enucleation procedure. 16 We investigated the effect of pre-enucleation radiotherapy on 
proliferation (chapter 6) and DNA-ploidy (chapter 7). In the search for prognostic factors 
we investigated the prognostic value of DNA-ploidy (chapter 7), proliferation parameters 
and tumorsuppressor gene expression (chapter 8). Furthermore we studied the role of the 
plasminogen activator system (chapter 9) and the expression of neural cell adhesion 
molecules (NCAM) in the acquisition of malignant properties of uveal melanoma (chapter 
10). 
RefeI'ences: page 37 
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CHAPfER 2: Malignant Melanoma of the Uveal Tract 
2.1 Epidemiology 
2.1.1 Incidence and geographic factors 
The epidemiologic aspects of uveal melanoma have been extensively reviewed by Egan et 
at. 17 Melanoma of the uvea is the most common primary intraocular malignancy in adults. 18 
The estimated incidence is six cases per one million subjects per year in the western 
population.2,19,10,21 The incidence of uveal melanoma in whites is eight times that in blacks 
and threefold greater than that in certain Asian groups.22 In the Caucasian population 
individuals with light irides have three times the risk of developing uveal melanoma 
compared to persons with brown eyes.23 Early life exposures to sunlight have been found to 
be especially important in the development of intra·ocular melanoma." Recent 
epidemiological studies have reported an elevated risk for Northern European ancestry, 
light skin color, the presence of 10 or more cutaneous nevi, use of sunlamps and intense 
sun exposure." Holly found an increased risk of developing uveal melanoma for the 
apparent effects of UV exposure (severe eye burn, snow blindness), and for host factors, 
like eye color and a propensity to burn rather than tan." These findings implicate sunlight 
as an environmental risk for this disease. It is believed that the choroid and ciliary body are 
protected from UV exposure and also from a large portion of the more energetic 
wavelengths of the visible spectrum by the overlying retina and retinal pigment 
epithelium." We must, however, conclude that although there is ample epidemiological 
evidence for a role of UV radiation as a risk factor in developing uveal melanoma, it is 
unlikely that UV radiation is able to reach the choroid. The exposure to sunlight would also 
not explain the pathogenesis of melanomas arising in the ciliary body that is not in the 
direct path of light entering through the pupil, but may be reached by scattered light. For 
iris melanomas the role of sunlight seems more convincing: iris melanomas tend to occur in 
the inferior sector of the iris." The upper eyelid shields the superior half of the iris from 
sunlight. The tendency for this tumor to appear in blue·eyed individuals is also supportive 
of the role of actinic damage in these tumors. However the incidence of iris melanomas is 
much smaller compared to those arising in the ciliary body or choroid. Another argument 
against the direct role of UV radiation in uveal melanoma might be that incidence and 
mortality rates for uveal melanoma are changing very little in Europe, North America, 
Japan and Australia. 29 This finding is in contrast to the rapid increase of the incidence of 
cutaneous melanoma. 
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2.1.2. Age and sex 
Although congenital malignant melanoma of the uvea has been reported," it is rarely 
encountered in children or young adults. In most series, the median age at diagnosis is 
about 55 years.20 Raivio found uveal melanomas to be most frequent in women in the sixth 
decade of life, and in males in the seventh.' Patients older than 40 years of age at the time 
of treatment have a worse prognosis than younger patients. 20·31 
2.1.3. Genetics 
Cutaneous melanoma is an inherited disease in about 10% of cases,32 but for uveal 
melanoma only about 13 clusters occurring among relatives have been reported; sometimes 
involving more than 2 generations. 33 Inheritance is reported to be most likely autosomal 
dominant with partial expression or incomplete penetrance. J.I An inheritable form of 
cutaneous melanoma is known as the familial atypical multiple mole melanoma 
(FAMMM), B-K mole syndrome or the dysplastic nevus syndrome: family members of 
persons with large numbers of dysplastic nevi have a high risk of developing cutaneous 
melanoma. A percentage of these cases is sporadic rather than familial. It is unclear 
whether a risk relationship exists between sporadic and familial dysplastic nevus syndrome 
and ocular melanoma," but has been suggested by a Dutch study.36 However, heredity is 
clearly not a major determinant of uveal melanoma. 
2.1.4. Hormonal factors 
Several observations suggest that hormonal factors are involved in uveal melanoma. Higher 
incidence rates of uveal melanoma have been found in young women than in young 
men; 19,37 an increased risk has been found for ocular melanoma after use of estrogen 
substitutes and a decreased risk among women who had undergone ovariectomy. 37 A 
related observation is the finding that survival for women with uveal melanoma seems to be 
more favorable than for men. 20·31 Gynecologic cancers tend to be more common in female 
patients with uveal melanoma." A recent study found a decreased risk for women, who had 
ever been pregnant: the largest difference was observed between nulliparous and parous 
women. No other reproductive factors, including use of oral contraceptives or 
postmenopausal estrogens appeared to be related to the risk for uveal melanoma in that 
study.39 A larger case~control study of cutaneous melanoma and reproduction variables 
have shown inconsistent results.40 
2.1.5. Occupational exposure 
The only specific occupational exposure which has been linked to uveal melanoma is 
welding, as did exposure to UV. 26 
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2.1.6 Nevi, ocular melanosis and neurofibromatosis 
The annual rate of transformation to malignant melanoma is probably in the range of 1 per 
5000 choroidal nevi each year. Although the absolute risk of choroidal melanoma in 
individuals with choroidal nevi is low, the risk may still be greater than that in individuals 
without choroidal nevL" Ocular melanocytosis and oculodermal melanocytosis (Nevus of 
Ota) are rare typically congenital unilateral hyperpigmentations, involving the uvea, scleral 
canals and episclera and predispose to uveal melanoma. 17 
Neurofibromatosis is possibly associated with cutaneous" and choroidal melanoma.42 
Although it has been suggested that neurofibromatosis patients have an increased incidence 
of uveal melanoma,43 the number of reports is small. <H 
2.1.7 Associated extraocular primary cancers 
One study on 400 uveal melanoma patients revealed that the overall prevalence of cancers 
diagnosed in these patients was over two times greater than the expected prevalence; basal 
cell carcinomas were excluded. They indicated a link between cutaneous and uveal 
melanoma.38 In contrast} another study on 407 uveal melanoma patients found no elevated 
risks for a history of other prior cancer.45 
2.2 Melanoma of the Iris 
Melanomas of the iris are rare and account for 3 to 12 % of uveal melanomas. Contrary to 
the relatively poor prognosis of malignant melanomas of the choroid and ciliary body, the 
vast majority of iris melanomas is known to consist of relatively benign, non-metastasizing 
lesions: only 37 cases of iris melanomas with presumed metastasis have been reported in 
the literature. 40 From a clinicopathologic study of 189 lesions it was concluded that most of 
these lesions are in fact biologically benign, "progressive," or "active" nevi, even though 
they might have produced a surface plaque growth onto the trabecular meshwork and 
peripheral cornea.28 Fine needle aspirations of the iris are not helpful in differentiating nevi 
from small melanomas, but can be useful in differentiating melanocytic tumors from other 
benign tumors or metastatic lesions. 
Conservatism is recommended in the management of iris tumors. Enucleation of an iris 
melanoma should be considered only if the tumor is too extensive (extrascleral growth, 
irreversible tumor-induced glaucoma) to be managed by other methods (local resection) or 
if the eye has no salvageable vision. 46 
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2.3 Melanoma of the Choroid and Ciliary Body 
In contrast to iris melanomas, tumors of the choroid and ciliary body pose a serious threat 
to life. The location of the anterior margin of the tumor, anterior to the equator of the eye 
is associated with an unfavorable outcome. 10 Most uveal melanomas arise from the choroid. 
The clinical symptomatology depends on the location of the tumor: tumors of the posterior 
pole cause early symptoms. They can be diagnosed by ophthalmoscopy and 
ultrasonography. Evidence of growth can be established by serial fundus photography. A 
recent clinicopathological study reported a clinical misdiagnosis rate of only 0.48 %.47 In 
clinical atypical cases fine needle aspiration biopsy, using a 22-gauge needle, can be 
reliable in differentiating amelanotic choroidal melanoma from choroidal metastasis and 
other amelanotic fundus lesions.48 Relative contra-indications to fine-needle aspiration of a 
suspected intra-ocular tumor are I) the presence of an intra-ocular mass in which the 
diagnosis is reasonably well established on the basis of ocular examination and non-invasive 
diagnostic studies 2) a small melanocytic choroidal or iris lesion in which the differential 
diagnosis is between a large nevus and a small melanoma and 3) the presence of a localized 
mass, for which local resection is contemplated.48 
The diffuse, flat malignant melanoma of the choroid is rare, and characterized by diffuse 
insidious growth throughout the uvea. Clinical diagnosis of these tumors is difficult and 
usually made in later stages; diffuse, nat melanomas tend to have a particularly poor 
prognosis. 
The growth of uveal melanoma may occur in three directions, i.e. outward (through the 
sclera), inward (through Bruch's membrane towards the vitreous) or in the uveal plane. 
Scleral invasion occurs along the scleral emissary veins and may be found very early in the 
course of the disease. Extrascleral growth is observed in between 3.8% and 40% of the 
cases. 31 .49 Once Bruch's membrane has been ruptured, subsequent tumor growth is most 
extensive into the subretinal space. Bruch's membrane exerts an elastic restraining effect 
around the rupture, leading to a mushroom shaped mass in which blood ou\now is impeded 
(Figure I). Changes at the front of tumor invasion such as loosening of the cellular union 
and transformation to a more malignant cell type, has not been demonstrated light 
microscopically." 
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2.4 Classification 
Figure 1: A mushroom shaped maligllllilt melanoma 
oJlhe posterior lweal tract, breaking through 
Bruch's membrane (arrows). Hematoxylill/eosin, 
original magllificatioll x n. 
Malignant melanomas have a spectrum of cell types, ranging from thin and plump spindle 
cells to epithelioid cells. In 1931 Callender developed a cytologic classification of uveal 
melanomas. 51 The following types of melanoma cells were recognized in the original 
Callender classification. I) Spindle A cells are uniform, slender spindle-shaped cells, 
containing fusiform nuclei often showing a longitudinal streak (Figure 2a). 2) Spindle B 
cells are plumper spindle cells with larger ovoid nuclei, and conspicuous nucleoli (Figure 
2b). Spindle cell tumors tend to grow in a compact cohesive fashion, and they generally 
have a dense framework of reticulin fibers. Callender defined a fascicular type melanoma 
as a tumor composed of spindle B cells arranged in columns, or fasciculi (Figure 2c), often 
orientated at right angles to a centrally located capillary, which is now classified as a 
spindle cell melanoma. 3) Epithelioid cells are much larger, polyhedral, sometimes very 
pleomorphic cells with abundant acidophilic cytoplasm, large pleomorphic nuclei and large 
acidophilic nucleoli (Figure 2d). These cells grow less cohesively than spindle cells and are 
not surrounded by a network of reticulin. Melanomas of the mixed cell type are composed 
of a mixture of epithelioid and spindle cells. Later another category, "necrotic" melanoma 
was introduced. In addition small epithelioid cells (Figure 2e) and large lipid- and/or 
glycogen containing tumor cells were recognized (Figure 21). This classification has 
appeared not to be sufficiently reproducible." 
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Figure 2: a} Spindle A cells, characterized by slender spbulle·shaped cells. cOlifaillillgjllsijorm nuclei ofte1l 
showing a longitudillal streak (arrou~. b) Spindle B cells: plumper spilllile cells, wi,h larger o~'oid Jluclei, alld 
conspicuous lIucleoli. c) Fascicular type melanoma, composed oj spi/Ulle cells arranged ill COIUI1U1S, d) 
Epithelioid cells: less cohesive, polyhedral pleomorphic cells with MIII/dallt acidophilic cytoplasm, large lIuclei 
alld large acidophilic 1/ucleoli. e) Small epithelioid cells. j) Large clear cells: lipid multor glycogen containing 
tumor cells. (a -f' Hel1latO).ylillleosill, original magnificatioll x 361). 
McLean et al. demonstrated that spindle cells include a spectrum of benign and malignant 
cells and they proposed a modification of the Cal/ender classification: spindle cell 
melanomas, mixed cell melanomas and epithelioid cell melanomas. >J.5-I This classification is 
currently applied. They also demonslrated Ihal all melanomas conlaining epithelioid cells 
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had more than 50% chance of metastatic spread, but when the epithelioid cells were small 
the prognosis was not quite so bad. Although important trends have emerged from 
retrospective prognosis studies, such as relevance of size and cell type, Markowitz et aI. 
noted the absence of information on study design and methods in 50% of 76 melanoma 
studies from 1966 to 1988." 
In recelll studies of uveal melanomas the presence or absence of any epithelioid cells 
(spindle cell melanoma versus a combination of mixed cell type and epithelioid cell tumors) 
has been used.3I ,56,51,58 
The biological behavior of uveal melanoma (tumor grade) depends not only on the cell type 
but also on several other factors including largest tumor dimension (LTD), especially LTD 
in contact with sclera,lO the location of the (umarIO,S9 and the presence or absence of 
extraocular extension. Tumors situated anteriorly are more associated with subsequent 
metastases than those located posteriorly. The leading predictors of survival are LTD and 
the presence of epithelioid cells: 10." LTD d 2 mm and less than two epithelioid cells per 
high power field (HPF) is associated with a favorable outcome.1O A meta-analysis of 
melanoma reports between 1966 and 1988 indicated that the combined weighted estimates 
of 5-year mortality rates following enucleation were 16% for small (LTD dO mm) tumors, 
32% for medium (LTD: 10-15 mm), and 53% for large ( LTD> 15 mill) tumors.' By 
univariate analysis cell type and LTD share a similar level of correlation with death from 
uveal melanoma, but only a limited correlation between cell type and LTD could be 
demonstrated. 57.58 Recent investigations have suggested that the presence of vascular 
networks, defined as at least three back to back closed vascular loops (Figure 3), is a 
feature strongly associated with death from metastatic melanoma. 6O,61 
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Figure 3: Closed vascular networks ill 
uvea/melalloma. Periodic~acid Schiff. 
withollt hemato:tylillleosill 
cOlllllersta;/J;/lg, magnification x 36/). 
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Other significant factors in the Cox proportional hazard model included in that study (in 
descending order of importance) LTD, mitoses, the parallel with cross-linking vascular 
pattern, age, the presence of tumor-infiltrating lymphocytes (TIL),60 and male gender."·60 
Cell type and tumor location did not appear to be an important prognostic parameter in the 
stepwise modelling in that study. 
Tumor stage indicates the extent of spread from the primary site: this can be recorded 
according to the pTNM pathologic classification," which is shown in Table 1. 
Table 1 TNM Classificatioll oflllaligllal1l1l1elalloll1a of the posterior uvea 
Pre-treatment Clinical Classification 
T - Primary Tumor: Ciliary body 
Tl Tumor limited to the ciliary body 
T2 Extension into the anterior chamber andlor iris 
1'3 Extension into choroid 
T4 Extra-ocular extension 
T - Primary Tumor: Choroid 
Tl* dO mm LTD alld d mm elevation 
Tla: <7 mm LTD alit! <2 mm elevation 
Tlb: > 7-10 mm LTD alit! > 2-3 mm elevation 
T2* > 10-15 mm LTD alit! > 3-5 mm elevation 
T3* > 15 mm LTD or 5 mm elevation 
T4 Extra-ocular extension 
N - Regional Lymphnodes 
NO No regional lymph node involvement 
NI Evidence of regional lymph node involvement 
M - Distant metastases 
MO No evidence of distant metastases 
MI Evidence of distant metastases 
*: When LTD and elevation show a difference in classification, the highest calegoI)' should be used for 
classification. 
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Table 1 (continued) TNM Classificatioll of mali8"am melalloma of the poslerior IIvea 
P. TNM Post-surgical Histopathological Classification 
pT- Primary Tumor: Cilimy Body alld Choroid 
G - Histopathologic Grading 
G I Spindle cell melanoma 
G2 Mixed cell melanoma 
G3 Epithelioid melanoma 
GX Grade can not be assessed 
S - Scleral invasion 
SO No evidence of scleral invasion 
S 1 Evidence of intrascleral invasion 
S2 Evidence of extrascleral invasion 
v - Venous Invasion 
VI Veins in melanoma contain tumor 
V2 Vortex veins contain tumor 
VX Venous invasion can not be assessed 
pN and pM categories correspond to clinical Nand M categories 
STAGE GROUPING: Ciliary Body and Choroid. 
Stage I TI NO MO 
Stage II T2 NO MO 
Stage III T3 NO MO 
Stage IVa T4 NO MO 
Stage IVb any T NI MO; any T any N MI 
This classification combines tumor size (LTD, tumor height, presence Of absence of 
extrascleral growth)(T), cell type (G), spread to regional lymph nodes (N) and presence or 
absence of metastases (M). The practical value of this classification for uveal melanoma is 
limited: uveal melanomas do not metastasize to regional lymph nodes, and the presence of 
clinically detectable metastasis at the time of diagnosis of the primary tumor is rare. 
Furthermore LTD is in most studies a more important prognostic factor compared to the 
presence of extrascleral growth; tumor height seems of minor importance in this respect. 
Combining these factors does not provide additional value. 63 
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2.5 Survival of Choroidal Melanoma Patients 
In a 7 112 year follow-up study from a series of 234 patients treated in Rotterdam between 
1971 and 1990 the survival rate was 74%.'" These survival curves are similar to recently 
published survival curves. 31." Survival for women with choroidal melanoma was more 
favorable than for men.'" This is concordant to the findings of Folberg et al.31 and Jensen. 20 
Unfortunately a proportion of patients with relatively favorable tumor characteristics, like 
small size and pure spindle cell composition, still develops metastases. Survival data 
indicated that uveal melanoma create a peak incidence of mortality during the second and 
third years following enucleation, irrespective of LTD. Therefore it has been argued that 
surgical manipulation of the eye during enucleation could mechanically squeeze tumor cells 
into the blood stream, thus enhancing dissemination." Proponents of this hypothesis point 
to the lack of detectable metastases when the patient first presents. However, in patients 
treated by enucleation tumor cells must have disseminated prior to or during treatment, 
probably due to micrometastases. Survival time for patients dying of metastatic disease is 
primarily a function of the growth rate of the tumor cells." Survival curves for Tl tumors 
showed that the peak in death rate for these relatively small melanomas shifted to the fourth 
postoperative year, being half the size of the peak for T4 tumors.63 Manschot postulated 
that -based on calculated doubling times (Td's) of skin melanomas- Td's of uveal 
melanomas with a significant epithelioid cell component might vary between 30 and 100 
days, and Td's of spindle cell melanomas between 100 and 365 days."'" In a review of 39 
published calculated doubling times of uveal melanomas 36 appeared to be longer than 60 
days. Metastatic death occurred 35-40 Td's after dissemination. The shortest interval 
between dissemination and metastatic death in individual patients was therefore calculated 
as 35 x 60 days = 6 years. It was postulated that all metastatic deaths within these 6 years 
are due to pretreatment dissemination." Our inability to predict survival with a high degree 
of accuracy is due to a lack of understanding of the factors which initiate and control the 
metastatic process in uveal melanomas. 
2.6 Thel'apeutic Modalities 
The management of malignant melanoma of the posterior uvea is still controversial. Small 
asymptomatic choroidal melanomas can probably be observed periodically until evidence of 
growth is documented. It is still generally agreed that enucleation is necessary for large 
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choroidal and ciliary body melanomas, and for melanomas that have caused giaucoma68,69,70 
Pre-enucleation radiotherapy has been employed in some centers, although recent doubts 
have been raised to its effectiveness in preventing metastasis.6l ,71,n Other modes of 
treatment include local resection for melanomas located nasally and those located more than 
one disc diameter from either the optic disc or fovea," laser photocoagulation for some 
small choroidal melanomas," and radiotherapy." 
Currently, radiotherapy is the most widely advocated treatment modality for medium-sized 
melanomas by some authors. ".70 The most commonly used type of radiotherapy has been 
the episcleral application of a radioactive plaque. Iodine, Cobalt, Iridium, and Ruthenium 
plaques are being used for this purpose. Another method of radiotherapy is charged particle 
irradiation." The two methods of radiotherapy seem to have equal results with regards to 
the development of systemic metastatic lesions. ".70 
Orbital exenteration is sometimes necessary for advanced uveal melanomas with massive 
extraocular extension,"·70 although it is questionable if this prolongs life expectancy. 
Currently, the most frequently advocated treatment methods are enucleation and episcleral 
plaque brachytherapy. On the basis of currently available information, 5-year survival rates 
for patients who receive radiotherapy are similar to those for patients treated by 
enucleation." Studies with limited follow-up have shown that 5 to 10% of patients who 
receive radiotherapy ultimately require enucleation of the affected eye because of recurrent 
tumor growth or radiation-induced complications.77 
Manschot postulated that the shortest interval between dissemination and metastatic death 
may be calculated as 6 years. Therefore local therapy cannot influence the survival rate 
within the first seven post-therapeutic years."'" An analysis of published, 
histopathologically studied irradiated melanomas revealed a retained reproductive 
integrity." He postulated that the risk for post irradiation exponential growth cannot 
become manifest before a lO-year follow-up study, leaving few justifiable indications for 
radiotherapy." A large collaborative study to evaluate the relative effectiveness of 
enucleation and iodine plaque radiotherapy is under way." 
Recently a reverse transcription/polymerase chain reaction amplification of the tyrosinase 
gen has been used to detect circulating tumor cells as first sign of dissemination from uveal 
melanoma. 8o This may be important when considering the administration of adjuvant 
therapy. 
Currently no effective treatment exists for metastatic uveal melanoma. The effectiveness of 
new approaches for the management of metastases, involving interferons, interleukin, and 
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combination chemotherapy has not been determined, Intrahepatic administration of 
chemotherapy for hepatic involvement of metastatic uveal melanoma is under study, When 
an effective systemic treatment for metastatic uveal melanoma has been found, early 
administration as an adjuvant to primary 'treatment for patients with a high risk of 
developing metastasis may provide the best strategy for control of systemic spread,81 
Immunotherapy is under study, 
References: page 37 
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3.1 Morphometry and DNA Analysis 
The interobserver error of the conventional Callender classification has proven to be 
large. 52." The original Callender system was simplified in order to reduce the number of 
categories, which has improved the correlation of histologic features with malignant 
behavior. 54 However, since morphology varies as a continuum, morphological classification 
schemes are inherently arbitrary and subject to variations in interpretation." Subsequently, 
a semi-quantitative system was developed to estimate the percentage of epithelioid cells in 
each tumor lO and the number of epithelioid cells and inverse standard deviation of the 
nucleolar area. 83 This refined method still remained SUbjective. Furthermore, it has been 
shown that measurements of LTD made from glass microslides correlate with direct 
measurements taken from the cut surface of the globe at the time of gross examination, if 
the eye was cut to obtain representative sections.8-\ 
Methods have been devised to measure cytologic features objectively. One of the early 
methods developed was measuring the standard deviation of nucleolar and nuclear features, 
which confirmed the value of nuclear pleomorphism for predicting the malignant potential 
of uveal melanomas." The standard deviation of the III1c1eolor area (SDNA) proved to be a 
useful measure of the malignancy of intra-ocular melanomas, especially when coupled with 
LTD. ".87 The standard deviation of both nucleolar area and circumference correlated highly 
with survival: the nucleolar area was usually greater and more pleomorphic in the more 
malignant type of uveal melanoma (epithelioid or mixed versus spindle cell tumors). 
Unfortunately this method requires an elaborate specially designed system. A simpler 
system was developed to calculate the mean of the diameters of the ten largest nucleoli 
(MLN) encountered in a strip 5 mm long and one oil immersion field wide through the 
center of the tumor. 87,88 
A comparison of prognostic covariables for uveal melanoma revealed that LTD, Callender 
cell type, SDNA and MLN correlated equally with tumor related death. MLN can be 
measured more easily than SDNA and is more reproducible than cell type and is therefore a 
useful prognostic parameter." Multivariate analysis revealed that adding LTD as a 
prognostic covariate to either cell type, SDNA, or MLN yields a substantial increase in 
prognostic value. 6,s9 A recent study demonstrated that, using multiple Cox regression 
models, MLN failed to exert any effect on outcome after enucleation. These authors found 
the presence of closed vascular loops to be the most statistically dominant histologic 
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prognostic characteristic. 9O 
A morphometric analysis studying Iluc/ear as well as nucleolar features revealed that the 
standard deviation of nuclear area was the most significant variable, followed by the 
difference between nuclear and nucleolar areas, SDNA." A combination of (tumor-
induced) glaucoma and standard deviation of nuclear area appeared to be the most 
significant prognostic cornbination. 58,91 Recently syntactic structure analysis has been 
applied to uveal melanomas. This is a mathematical method describing the basic structural 
units such as cells, glands and vessels as a network." This technique may be able to 
differentiate between various Callender cell types." 
Nucleoli are sites of active RNA synthesis, and a relationship between nuclear RNA 
content and prognosis was investigated by flow cytometry using acridine orange, a 
metachromatic fluorochrome: the nuclear RNA content appeared to be an independent 
prognostic indicator in uveal melanomas, and increased RNA content was associated with a 
worse prognosis.92 
Nucleolar organizer regions (NORs) are outpouchings of nucleolar DNA, that direct 
ribosomal RNA transcription. Silver staining of the nucleolar organizer regions (AgNORs), 
visualizes the size and number of nucleolar organizer regions as black dots, seemingly 
reflecting or predicting cellular proliferation. Application of this method to a series of 
uveal melanomas disclosed a correlation of AgNOR counts with mitoses and tumor size; 
however, the prognostic value of AgNORs remains to be established." 
DNA flow cytometry has shown to be a reliable quantitative method of determining the 
nuclear DNA content (ploidy) of a tumor cell sample. For uveal melanoma it has been 
shown that ploidy abnormalities correlate more closely with survival than the standard 
histologic parameters. ".95 
DNA quantitation can also be carried out by static image analysis, usually by measuring the 
amount of light transmitted through tumor cell nuclei in a Feulgen stained specimen. For 
uveal melanomas it has beeu found that all spindle A cells are diploid and most tetraploid 
peaks are formed by epithelioid cells.96 This method, however, does not appear to have 
additional prognostic value.97 
Bromodeoxyuridine, a thymidine analogue, is incorporated during the synthesis phase of 
the cell cycle. Measurements of DNA synthesis by bromodeoxyuridine incorporation in 
uveal melanoma showed destruction of reproductive integrity of melanomas, which 
received 20 Gy pre-enucleation radiation." 
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3.2 Genetic Abnol'malities 
3.2.1. Cytogenetics 
The association of consistent chromosomal aberrations with particular types of cancer has 
led to the identification of some of these genes and the elucidation of their mechanism of 
action. The common tumor chromosome aberrations are generally classified as structural or 
numerical. Structural alterations include translocations, inversions, deletions, insertions, 
and amplifications, whereas numerical abnormalities are losses or duplications of whole 
chromosomes, 
For cutaneous malignant melanoma and their cell lines, frequent involvement of 
chromosomes 1,6,7,9 and 11 in structural aberrations has been reported,99.lOJ It has been 
suggested that chromosome 9 plays a role during the development of cutaneous malignant 
melanoma, whereas chromosomes 2,3 and 6 are most likely associated with progression. lot 
Cytogenetic studies of uveal melanomas revealed that monosomy of chromosome 3 and 
multiplication of chromosome 8q do not occur randomly in uveal melanoma. IOS.1I1 
Monosomy 3 and gain of 8q have exclusively been demonstrated in ciliary body 
melanomas, 108.109 and may therefore be associated with a subgroup of uveal melanomas with 
poor prognosis.101 Furthermore aberrations of chromosome 6 (loss or gain) have been 
described,IC)$,t07,1I2 In cell lines obtained from metastatic uveal melanoma no consistent 
chromosomal aberrations have been demonstrated. 1I3 
3.2.2 Oncogene activation 
The genetic damage found in cancer cells comprises two different categories 1) dominant 
mutations which can activate proto-oncogenes to become oncogenes, 2) recessive mutations 
in target genes known as tumor suppressor genes or anti-oncogenes. They are called 
recessive because both copies must be inactivated for tumor formation to occur, 
It is generally accepted now that molecular alterations in oncogenes and tumor suppressor 
genes are responsible for the conversion of a normal cell into a tumor cell. Usually these 
genes exert normal functions in cell proliferation and differentiation." 
Little research has been carried out to identify and analyze the role of oncogenes and tumor 
suppressor genes in the development and prognosis of choroidal melanoma. Several 
oncogenes, including c-myc, have been mapped to 8q.103."4 The expression of c-myc 
oncoprotein has been investigated in uvea!" melanomas and compared with other prognostic 
factors. Positive staining for c-myc protein correlated with proliferative index in diploid 
tumors, and with HMB-45 staining, but not with cell type.'" In a study on prognosis, the 
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percentage of c-myc positive cells was strongly associated with tumor-related death. 
Furthermore a strong correlation between c-myc and the Mib-I defined proliferative index 
was found. 116 
Point mutations in the N-ras gene occur in cutaneous malignant melanomas. In patients 
with the N-ras mutation, sun exposure could have been the etiologic agent of these 
melanomas,lI7 For uveal melanomas no N-ras mutations were detected in any uveal 
melanoma studied,118.119 
The expression of the oncoproteins c-neu (c-erb-B2: epidermal growth factor receptor) and 
ras were also analyzed with specific MAbs in a small series of uveal melanomas: in one 
metastasizing melanoma marked expression of ras was obvious. 120 
Recent evidence suggests that mutation of the p53 suppressor gene (named for the protein it 
encodes, p53) is one of the most common abnormalities found in human cancers,l2I This 
gene is located on the short arm of chromosome 17 and encodes a 53 kD nuclear protein 
that appears to be involved in regulating the cell cycle. The normal p53 product has been 
shown to act as a tumor suppressor, but various point mutations within the coding region of 
the gene inactivate or alter this function. These mutations arise relatively late in neoplastic 
progression and may correlate with malignant transformation. However, to evaluate p53 as 
a diagnostic marker correlations between p53 mutation (DNA sequence), protein 
overexpression (immunocytochemistry positivity), and tumor behavior need to be 
considered.'" For cutaneous melanoma significantly increased prevalence of mutant p53 
was found in metastatic melanoma, compared with primary tumors.123 In contrast, other 
investigators found that the p53 staining was not correlated to subsequent development of 
local metastases and a significant decrease of p53 protein in metastatic lesions was found, 
as compared with the corresponding primary tumors. "4 Staining for mutant p53 protein 
expression was found in 12 out of 18 uveal melanomas, whereas choroidal nevi were 
negative. In two melanomas expression of the p53 protein was confirmed by the 
demonstration of mutations in exon 7. These observations suggest that acquisition of 
abnormalities of the p53 gene may be an important step in the progression of uveal 
melanoma.125 Recently, mutant p53 has been demonstrated in museum specimens of a 
family with a history of four generations of uveal melanoma associated with breast 
cancer. 126 
Recently, homozygous deletions of a gene (Multiple Tumor Suppressor I) have been 
reported in a wide variety of tumors, including cutaneous melanomas. This gene encodes a 
protein, previously identified as inhibitor (pI6) of an enzyme called cyclin-dependent 
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kinase 4 (Cdk4), which is involved in the cell division cyele. m CurrenUy, uveal melanoma 
cell lines are under study. 
Examination of mRNA levels of 21 different oncogenes, anti-oncogenes, growth factors 
and proteases in 17 cu!aneous melanoma cell lines revealed a significant correlation 
between c-myc, p53 and c-src-I (tyrosinase-kinase) levels, and between p53 and c-erb-B2 
(EGF-receptor), which may be due to common regulatory control of these genes in cells of 
the melanocytic lineage. '28 This is in accordance with the view that oncogenic 
transformation is a multistep process, involving activation of at least two genes. 129 
So far no single gene has been shown to participate in the development of human cancers. 
For uveal melanoma, research in the field of molecular genetics has been limited. Further 
identification of tumor suppressor genes or oncogenes that participate in the cell cyele of 
uveal melanoma seems necessary. 
3.3 lnunullology 
Cutaneous and uveal melanomas are considered to be relatively susceptible to immunologic 
influences because of reports of spontaneous regression,'30 and because of the delayed 
appearance of metastatic disease, sometimes decades after enueleation.13I Five to 12% of 
uveal melanomas have tumor-infiltrating lymphocytes (TIL).'" The number of cells is 
variable (0.1-29%), but usually low (mean 4,5%).133 Immunohistochemical analysis of TIL 
revealed that T cells predominate in 74% of these cases, usually scallered, whereas B cells 
constitute a minority, usually present in elumps.'3-I This was similar to the findings by flow 
cytometric analysis of TIL.'" Remarkably, the presence of more than 100 TIL per 20 HPF 
in uveal melanoma is associated with a decreased survival rate."·135 T-Iymphocytic 
infiltration was associated with death due to metastasis. 13-1 This is the opposite of what is 
observed with most solid tumors in adults, where the presence of TIL is associated with 
increased survival. It has been speculated that dissemination of tumor cells is required for 
the generation of a T lymphocyte-mediated immune response. Because the eye lacks 
lymphatic drainage the primary antigen processing is in the spleen.'" Without lymphatic 
drainage uveal melanomas may be less likely to disseminate than most neoplasms.6•13-I 
Expression of the histocompatibility antigens HLA I and II on neoplastic cells may be 
important in the host-tumor interaction. HLA A,B,C antigen are detectable in most primary 
cutaneous melanomas and HLA-DR expression is associated with increased thickness and 
early metastasis. 136 In cutaneolls melanoma, class I and II antigen expression appeared more 
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pronounced in the presence of a lymphocytic infiltrate. 137 
3.4 Melanoma Associated Antigens 
Immunohistochemical study is now commonly used by pathologists in the differential 
diagnosis of anaplastic tumors. Several MAbs recognizing melanoma associated antigens 
(MAA) in routinely fixed, paraffin·embedded tissue are currently used (Table I). With 
antisera generated against the SIOO protein, immunoreactivity was noted in 90 - 97% of 
primary choroidal melanomas. m .", In contrast, only 15% of the tumors stained with a 
MAb specific for both S 100. and S I 003, whereas 85 % of all cutaneous melanomas reacted 
with this antibody. These findings suggest the possibility that a variant SIOO protein exists 
in choroidal melanoma.'" This has been confirmed at the mRNA level by a quantitative 
PCR method: choroidal melanomas expressed little or no SlooB.'40 Although quite 
sensitive, antibodies to S 100 are not melanoma-specific. 
The monoclonal antibody HMB-45 labels a cytoplasmic antigen produced by fetal 
melanocytes and melanoma cells of adults. '" It is specific and fairly sensitive for cutaneous 
melanoma and junctional nevi in formalin-fixed, paraffin-embedded tissue."2 HMB-45 
recognizes an antigen that is expressed by stimulated melanocytes.'43 More than 95% of 
choroidal melanomas express the HMB-45 antigen (Table 1)."8."'.,41 The HMB-45 antigen 
is immuno-electronmicroscopically found in melanosomes at stage II and III. This leads to 
the conclusion that proliferating melanocytes express the antigen.'41 Benign proliferative 
cells cannot be distinguished from malignant proliferating cells, with the aid of this 
antibody. Burnier et al. found that expression of HMB-45 appeared to be greater in active 
uveal nevi, than in inactive nevi, 139 
MAb NKI-C3 (gp90-34) was positive in 81 % of choroidal melanomas.'" The antigens 
recognized by MAb NKI-beteb (gp 100) are localized at the inside of premelanosomal 
vesicles. "0 This MAb has a striking similarity to HMB-45 (which also recognizes gp 100), 
but in addition recognizes resting adult melanocytes in skin. '" 
Interestingly, MAb CAM 5.2 to cytokeratins (CK) 8 and 18 reacted with formalin-fixed, 
paraffin-embedded primary uveal melanomas (38%), more often than with their cutaneous 
counterpart (6-14%)." 
Several other MAbs against uveal and cutaneous MAAs have been assessed on choroidal 
melanomas (Table 1)."...,0 
Many primary malignant tumors, including uveal and cutaneous melanomas, that initially 
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appear homogeneous by conventional light microscopy actually consist of heterogeneous 
groups of cells displaying different biochemical or antigenic properties. A light microscopic 
feature of some uveal melanomas is the presence of well-localized, morphologically distinct 
areas within the same tumor. These have been attributed to separate clones of cells in 
different growth phases. Such cells might be expected to have different and distinct 
antigenic and cytomorphologic characteristics. MAb MAb8-IH (Table I) bound selectively 
to these morphologically distinct areas, which appeared to have differences in mean nuclear 
area by cytomorphometric analysis. '49 
In order to evaluate the differences and similarities in antigenic expression patterns between 
cutaneous and uveal melanomas, a panel of MAbs directed against cutaneous MAAs has 
been applied on (frozen sections) of choroidal melanomas. Table 2 represents the markers 
expressed by the majority of uveal melanomas. MAbs NKIIC3 and NKIIbeteb had a high 
sensitivity for choroidal melanomas in frozen sections, I4S.I5I,152 Although marked variation 
of antigen expression in uveal melanoma was noted, certain patterns of antigen expression 
within individual lesion were present.'" A number of MAbs (NKI-beteb, NKI-C3, M-2-2-
4, Pal-MI'" and G7E2) stained uveal melanomas as well as cutaneous melanomas (Table 
2)."2 Of a panel of 18 MAA-MAbs applied on uveal melanomas, the expression of nine 
MAbs (TP39.I, TP36.I, 345.134, Mill, CL203.4, M2590) was similar to that in 
cutaneous melanomas. ". The studies revealed that the high molecular weight (HMW) 
antigen and ganglioside antigens were markedly less expressed on uveal melanomas than on 
cutaneous melanomas, 151,151,154 
The prognostic value of these markers remains to be established, although preliminary 
findings indicate that expression of NKI-beteb is related to a favorable prognosis in uveal 
melanoma, 155 
HLA class I stained 75%-85% of the uveal melanomas. 133.,"'''' No correlation has been 
found between HLA class I expression and uveal melanoma cell type. 133.156 Others observed 
an absence of class I expression on pure spindle melanoma,I>I or in contrast, expression of 
HLA class I to predominantly spindle cells. 1l2 HLA Class II was detected in a limited 
number of lesions,I33,151,m,156 A relationship between HLA class I or II with metastatic 
potential of uveal melanoma has, however, not been established. Uveal melanoma, that had 
been irradiated with 2x 4 Gy before enucleation, had a significantly lower lymphocytic 
infiltrate, and a significantly lower expression of HLA class 11."6 
It was concluded that the overall surface antigen phenotype of the uveal melanomas tested, 
differs markedly from that of cutaneous melanomas as defined by the panel of MAbs 
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directed against cutaneous MAAs. '52 This might suggest a different origin of the normal 
melanocyte giving rise to uveal tumors.1S2 
Table 1 Melanoma-associated al1fibodies expressed all choroidal melanomas, 
assessed 011 paraffill embedded tisslle 
MAb Specificity % les. % cells Reference 
S-100 monoclonal 90% 5-100% Burnier l39 
20%' >75%' Burnier139 
S-100 polyclonal 97% n.s. Kan-Mitchell'38 
MAb-079 S100./6 15% n.s, Kan-Mitchell'38 
HMB-45 100 kD 96% n.s. Kan-Mitchell'38 
HMB-45 100 kD 100% 5-100% Burnier139 
95%' >75%' Burnier lJ9 
HMB-45 100 kD 99% 5-100% Steuhl'44 
77%' >50%' Steuhl'44 
NKI-C3 gp90-34 81 % > 10% Ringens l4S 
ME491 HMW 87% 5-100% Folberg'" 
MAb8-lH 40-50 kD/O-MAA n.s. n,s. Donoso149 
4A3 55-60 kD/O-MAA n.s. 11.5, DamatolSO 
MAb: monoclonal alltibody. % les.: percelllage posilb'e stained lesiollS; % cells: percelllage posiri\'e cells. II.S.: 
1101 specified. ',. sensitMty. kD: kilodalto/l, HMlV: high molecular weight. O-MM: ocular melalloma-associated 
allligen. 
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Table 2 Markers expressed 011 Ihe majorilY oj choroida/me/alloma as 
recogllized by MAbs raised agaillsl ClIlalleOIlS me/allomas 
MAb Specificity % les. % cells Reference 
NKI-beteb 100 kD 86% >50% v.d.Pol l5I 
NKI-beteb 100 kD 100% >70% Carrell 52 
NKI-beteb 100 kD 100% >60% RingensI45 
NKI-C3 gp90-34 100% >60% RingensI4S 
NKI-C3 gp90-34 87% -100% Carrel ls2 
Pal-MI tr. rec. n.s <70% v.d.Pol'" 
Pal-MI tr. ree. 75% 20-80% Carrel152 
M-2-2-4 diff. ago 37% 5-100% v.d.Pol'" 
M-2-2-4 diff. ago 87% >80% Carrel 1S2 
G7E2 gpI20-110 87% 30-100% Carrel lS2 
225.28S HMW n.s. <70% v.d.Pol'" 
225.28S HMW 50% <50% Natali lS4 
G7A5 HMW 75% >80% Carrel ls2 
AMF-6 HMW n.s. n.s. v.d.Pol lsl 
AMF-6 HMW 50% >70% Carrel 1S2 
AMF-6 HMW 17% n.s. Ringensl4S 
AMF-7 MA-CAM-I 17% 5-100% v.d.Pol'" 
AMF-7 MA-CAM-l 63% -100% Carrel lS2 
CL 203.4 ICAM-I 87% >50% v.d.Pol'" 
CL 203.4 ICAM-l 42% 5-100% Natali'" 
Pal-M2 gp-95 75% 20-80% Carrel ls2 
Mell4 gp33-38 68% 5-100% Carrel 'S2 
Mel4IDl2 gp33-38 68% 5-100% Carrel lS2 
R24 GD3 50% 5-100% Carrel152 
MAb: monoclonal antibody. % les.: percelltage positive stailled lesiollS,' % cells: percellfage positive cells. kD: 
kilodaltoll. gp: glycoproteill. Tr. rec.: trallsferrin receptor. DiJ!. ag.: differentiation anligen 011 melanomas alld 
lIe~'i. HMW: high molecular weight. MA-CAM: mela/wma-associated cellular adhesio/J molecule. [CAM: 
illtercellular adhesion molecule. 11.S: /10/ specified. 
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3.5 Cell-Cell and Cell-Matrix Interaction 
3.5.1. Cell-cell interaction 
Cell adhesion molecules (CAM) are transmembrane proteins, connecting the cytoskeleton 
with the extracellular matrix. CAMs have been implicated not only in intercellular 
recognition, but also in morphogenetic events, regeneration, tumor invasion and metastasis. 
One CAM binds either to another identical CAM molecule on an opposing cell (homophilic 
binding) or binds to a receptor molecule of different identity (heterophilic binding). Of 
these adhesion molecules four families can be recognized: the immunoglobulin 
superfamily, the cadherin family, the integrin superfamily and the selectin family. "'.'" 
I) The immunoglobulin (lg) superfamily contains a series of CAMs which mediate Ca"-
independent cell adhesion. Most members of this family are single-path transmembrane 
glycoproteins, which act by homophilic recognition. Several subfamilies can be 
distinguished: i.e. the neural cell adhesion molecule (NCAM) and the carcino-embryonic 
antigen (CEA) subfamily. The intercellular adhesion molecules (lCAM), vascular adhesion 
molecule (VCAM) and leucocyte function-associated antigens (LFA) also belong to this 
family. ", 
2) The cadherins are Ca" -dependant CAMs, which bind cells by means of homophilic 
interaction. Among the better characterized cadherins are: E-cadherin (also known as L-
CAM), N-cadherin and P-cadherin. Each of the cadherins displays a unique pattern of 
tissue distribution. 157 
3) The integrin superfamily are mediators of cell-cell and cell-extracellular matrix 
adhesion. lntegrins are divided into subfamilies, each with a common 6-subunit capable of 
associating with a group of «-subunits. The ct- and 6-subunits in various combinations form 
at least 20 different types of integrins. The 61 (also known as very late activation or VLA-
antigens) integrins comprise a subfamily in which eight a chains combine with one B (the 
13,) chain. The vitronectin receptors share a common av chain. J58 
4) The selectins are adhesion-receptor glycoproteins with an EGF-like domain. They 
mediate the migration of neutrophilic granulocytes in developing inflammatory reactions 
and are found on endothelial cells and leukocytes (ELAM).I57 
Cell surface receptors which mediate cell-cell and cell-matrix interaction in processes like 
metastasis, have been the subject of intense investigation during the past decade. However, 
studies on uveal melanomas are few and so far limited to the 19-superfamily and the 
integrins. 
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For cutaneous melanomas ICAM-I and a related melanoma-associated CAM (MUC 18) 
have been studied in the context of metastatic behavior. 159,16O Some investigators found 
expression correlated with metastatic behavior'" but others demonstrated that these 
adhesion molecules occur on a full range of benign and malignant melanocytic lesions. '00 In 
uveal melanomas, cell adhesion molecule ICAM-l could not be detected'" and melanoma-
associated CAM AMF-7 was not'" or poorly expressed""'" (Table 2) compared to 
cutaneous melanomas. Others found ICAM-l on most of the uveal melanomas'"'''' (Table 
2) preferentially on the mixed and epithelioid cell type.'''' For cutaneous melanomas it has 
been suggested that loss of VCAM-l may be important in the development of metastases.'''' 
VLA-2 (integrin «2B1)'6I and the vitronectin receptor (<<vB3)'"'''' have been shown to be 
preferentially expressed in vertical growth phase of primary cutaneous melanoma lesions 
and metastases, suggesting a role in melanoma progression. In contrast to cutaneous 
melanomas, expression of the «2 integrin was rare in uveal melanomas, and «5 expression 
was found in all lesions. '61."5 Furthermore, «vB3 was not detected in any of the primary 
uveal melanomas, but in two out of four metastases. 1M All primary lesions strongly 
expressed «vJ35. 161,165 In contrast to cutaneous melanoma, it seems that determination of the 
integrin expression profile is not suitable for categorizing uveal melanomas as less 
malignant and highly malignant lesions. 
3.5.2. Cell-matrix interaction 
During several steps of tumor development, proteolytic degradation of the extracellular 
matrix and other tissue barriers is required,lM Tumor- or host-derived proteinases are major 
participants in this process. Different proteolytic enzyme systems are involved, including 
the matrix metalloprotease system'61 and the plasminogen activator-plasmin system. 16' For 
cutaneous melanomas, it has been demonstrated that expression of plasminogen activators 
(urokinase- and tissue type plasminogen activators: u-PA and t-PA) , their inhibitors, and 
urokinase receptors emerges in late stages of tumor progression,I69 Little is known about 
the role of proteases in the progression of uveal melanomas. An involvement of proteases 
in metastatic spread of uveal melanoma has recently been suggested by Cottam et al.,"0 
who detected the 72 and 92 kD type IV collagenase in culture medium of 15 primary 
cultures of uveal melanomas. Furthermore, t-PA activity in sllpernatants of primary 
cultures of uveal melanoma seemed to correlate with scleral invasion in the tumor lesion, 
whereas no u-PA activity could be detected. 17I A histochemical study of uveal melanomas 
revealed that t-PA is markedly present at the invasive front, but no relation with tumor 
related death could be established. Expression of lI-PA correlated with occurrence of 
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metastases. The involvement of the PA system in uveal melanomas differed from that in 
cutaneous melanomas.172 It is conceivable that in uveal melanomas other proteolytic 
systems are involved in metastatic spread. 
Several cytokines, secreted either by tumor cells, stromal cells or TILs, may act to enhance 
the invasive potential of tumor cells, leading to metastasis. 167 The most important cytokines 
are: tumor necrosis factor a (TNFa), interleukin-l (IL-l), transforming growth factor a 
and 8 (TGFa/8) and epidermal growth factor (EGF). Cutaneous melanoma cell lines, when 
treated in vitro with TNF«l7J or IL-1174 display enhanced metastasis upon injection in nude 
mice. Studies on uveal and cutaneous melanoma cell lines have shown that TGF8, used as a 
co-stimulant with TNF« or IL-l, selectively augments expression of the 92-kD type IV 
collagenase. 175 Detectable levels of TNF« have been found in one out of 16 uveal 
melanomas, occurring in one out of two patients who developed metastatic disease. 176 
The role of cell-cell and cell-matrix interactions, major elements in the acquisition of 
metastatic capacity of uveal melanoma, needs to be further elucidated. 
Sunm13ry 
Extensive research in the field of cytomorphometry yielded a substantial increase in 
prognostic value by investigating different aspects of the nucleoli in the cells of uveal 
melanoma. Furthermore DNA aneuploidy is reported to be a valuable prognostic marker. 
Aneuploidy occurs potentially in epithelioid melanomas, which have traditionally been 
regarded as having the greatest metastatic potential. The architecture of the 
microcirculation (the presence of networks of closed vascular loops) and LTD were found 
to be the most dominant histologic prognostic parameters. Unlike cytomorphometric 
techniques sU,ch as MLN and SDNA, which require specialized instrumentation, the 
detection of vascular patterns requires only a periodic acid-Schiff (PAS) without 
hematoxylin counterstaining stain and a green filter to enhance the visualization of these 
patterns. However, the reproducibility of this method remains to be established. 
Nevertheless, small or pure spindle cell tumors may also develop metastases. Several 
attempts have been made to identify characteristics in the uveal melanoma genotype and 
phenotype, which could be associated with the variation in metastatic potential. This search 
revealed considerable differences in cytogenetic findings between cutaneous and uveal 
melanomas. 
Patients with malignant melanoma may develop a cellular andlor humoral immune response 
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to melanoma-associated antigens expressed by the tumor cells. Although uveal and 
cutaneous melanomas share a large number of surface molecules, the specific surface 
phenotype of melanoma-associated antigens differs markedly between uveal and cutaneous 
melanoma. Furthermore, differences between uveal and cutaneous melanomas have been 
found with regard to cell-cell interaction and the proteinase systems, involved in the 
degradation of extracellular matrix degradation. Some of these findings may be related to 
the different (stromal) origin of the uveal melanocytes, from which uveal melanomas 
develop. 
Since early intraocular lesions are rarely available for research, in vitro models will play an 
important role in further investigations concerning uveal melanoma progression. 
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Summary 
An 83-year-old man with painless, bilateral visual loss developed multiple pigmented 
lesions on his penis, his buccal mucosa and the skin of his thorax. Bilateral multiple heavily 
pigmented areas were noted in his eyes. A bronchus carcinoma was detected. Postmortem 
histopathological examination of the eyes revealed bilateral diffuse uveal melanocytic 
hyperplasia (BDUMH), in addition to multiple pigmented melanocytomas and bilateral 
ciliary body malignant melanomas. Active proliferation of the benign uveal melanocytes 
was demonstrated by immunohistochemistry. Mucosal and cutaneous pigmentations have so 
far not been described as part of this paraneoplastic syndrome. 
Introduction 
Bilateral diffuse uveal melanocytic hyperplasia (BDUMH) is a rare but well known 
paraneoplastic syndrome, I associated with systemic malignancy. An essential feature of this 
syndrome is a preponderantly benign looking cytology of the melanocytic tumours. 2 We 
describe the clinical and histopathological features of BDUMH with active proliferation and 
bilateral ciliary body malignant melanomas. The multiple mucosal and skin pigmentations 
are an unusual feature of this syndrome. 
Case RCp0l1 
In 1990, an 82-year-old man presented with painless, bilateral visual loss for 3 weeks. He 
had been known to have a low grade non-Hodgkin's lymphoma for 6 years, which was in 
remission. Over one year he developed multiple pigmentations on his penis, the oral 
mucosa, and the skin, which were diagnosed as lentigo simplex. 
Ophthalmic clinical evaluation revealed visual acuities of 0.7 in both eyes. Fundus 
examination revealed a heavily pigmented tumour in the posterior pole of both eyes (Figure 
I). The peripheral part of both eyes contained multiple sharply defined, heavily pigmented 
areas. The clinical differential diagnosis included Gardner's syndrome and paraneoplastic 
syndrome. 
In 1991 an bronchus carcinoma was detected, of which the patient died in 1992. Autopsy 
was not permitted; however permission was given to remove the eyes. 
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Figure 1. Fundus of the right eye, 
with a hem·ily pigmented tUl1Iour ill 
,he posterior pole, which 011 
histological examination was 
consislellf »,illl meiallocyfoma. 
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On microscopic examination the choroid was diffusely infiltrated by plump spindle cells 
and small polyhedral cells. A few inconspicuous nucleoli were observed. Bleached sections 
of the heavily pigmented nodules showed a necrotic centre surrounded by large polyhedral 
cells with a basophilic central nucleus, compatible with melanocytoma cells. In both eyes 
the ciliary body was circumferentially thickened by atypical polyhedral cells with large 
nuclei, an irregular chromatin pattern and prominent nucleoli. A mitosis was sporadically 
observed. The tumour cells infiltrated the iris basis, the chamber angle, the trabecular 
system, and the pigment epithelium. Extrascleral, subconjunctival growth was noted in the 
right eye. In. the macula focal depigmentations or the retinal pigment epithelium was 
observed, with atrophy of the photoreceptors. 
On immunohistochemical examination the uveal melanocytes and the malignant melanoma 
cells stained strongly positive with HMB-45, S-100, and NKI-C3. There was weak staining 
with enolase and negative staining with Leu-? and neurofilaments. Uveal melanocytes 
showed at different places positive nuclear staining with a proliferation associated nuclear 
antigen (Ki-6?) (Figure2). The positive staining was observed in less than 1 % of the cells. 
On flow cytometric analysis, both the benign melanocytic hyperplasia and the ciliary body 
melanoma were diploid. 
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Comment 
~ Figure 2. Photomicrograph of 
posith'e lIuclear staining wi,h Ki·67 
(x361). 
Paraneoplastic BDUMH is a rare, but well known paraneopiastic syndrome associated with 
systemic malignancy.' The primary tumour, when identified, has been found in varying 
organs. OUf patient was known with a non-Hodgkin's lymphoma, which was in remission 
at the time of visual loss. In most patients described with BDUMH the visual complaints 
preceded the symptoms related to the primary tumour. The ocular and extra-ocular 
pigmentations in our patient developed before the clinical detection of the bronchus 
carcinoma. 
Although a preponderantly benign appearing cytology of the melanocytic hyperplasia has 
been mentioned as an essential feature of this syndrome, bilateral multiple uveal melanomas 
occurred in 4 patients described.'" 
The strong expression of HMB-45 in the melanocytic hyperplasia of our patient is 
consistent with melanocytic activation. '.6 Proliferation of the uveal melanocytes was focally 
demonstrated by a proliferation associated antigen. Both the benign melanocytic hyperplasia 
and the melanoma were diploid, which is consistent with relatively benign tumours. Active 
proliferation may have lead to malignant degeneration. The stimulus which leads to active 
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proliferation of preexisting anomalous melanocytes (that is,congenital uveal melanocytosis), 
is probably induced by a tumoral growth factor secreted by the primary tumour.' The 
visual loss of our patient can be explained by the depigmentation of the retinal pigment 
epithelium and the photoreceptor atrophy. 
The combination of OIallto's naevus and BDUMH has been described;' however, mUltiple 
extraocular lentiginous pigmentations have so far not been recognised as part of this rare 
paraneoplastic syndrome. 
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Mutations in codon 12, 13 or 61 of the ras genes, H-ras, K-ras and N-ras, convert these 
genes into active oncogenes (Barbacid, 1987). ras Gene mutations can be found in a variety 
of tumour types, although the incidence varies greatly (Bos, 1989). In animals, a wide 
range of xenobiotic agents are capable of inducing mutations in the ras oncogene family 
(Barbacid, 1987). Little is known about the involvement of mutagenic agents in the 
induction of ras mutations in humans. In cutaneous melanomas mutations of the N-ras gene 
(codon 13 and 61) were found in seven out of 37 tested cases (Van 't Veer et aI., 1989). 
The primary tumours of these 7 patients were exclusively located on continuously sun-
exposed body sites. These mutations were all near dipyrimidine sites, suggesting an active 
role for ultraviolet (UV) radiatiou in the induction of the mutations. Shukla et a!. (1989) 
found in one out of 22 tested primary cutaneous melanomas N-ras mutation in codon 61, 
but no details of sun exposure were available. Melanoma of the uvea (iris, ciliary body and 
choroid) is the most common primary intraocular malignancy in adults (Cutler & Young, 
1975). The incidence of uveal melanoma in whites is eight times the incidence in blacks 
and threefold greater then in certain Asian groups (Hakulinen et aI., 1987). In the 
Caucasian population individuals with light irides have three times the risk of developing 
uveal melanoma compared to persons with brown eyes (Gallagher et aI., 1985). Early life 
exposures to sunlight have been found to be especially important in the development of 
intra-ocular melanoma. (Tucker et aI., 1985). Recent epidemiological studies have reported 
an elevated risk for Northern European ancestry, light skin colour, the presence of 10 or 
more cutaneous naevi, use of sunlamps and intense sun exposure (Seddon et a!., 1990). 
Holly et a!. (1990) found an increased risk of developing uveal melanoma for the apparent 
effects of UV exposure (severe eye burn, snow blindness), and for host factors, like light 
eye colour and a propensity to burn rather than tan. These findings implicate sunlight as an 
environmental risk factor for this disease. The colour of the iris is determined by the degree 
of pigmentation; limited pigmentation leads to a blue or grey iris and high concentrations 
of melanin are present in brown irides. Melanin can absorb UV as well as visible light. 
To investigate possible UV mediated activation of N-ras genes we analysed 29 uveal 
melanomas for mutations. Table I summarises the patient data. The location of the intra-
ocular tumours is illustrated in Figure 1. 
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Table 1 Patient characteristics 
Clinical characteristics: 
Sex 
male 
female 
Histology 
Spindle cell type 
Mixed cell type 
Epithelioid cell type 
TNM classification* 
TI 
T2 
T3 
T4 
Pigmentation of the iris 
minimal 
moderate 
heavy 
unknown 
No. of patients: 
17 
12 
12 
8 
9 
2 
8 
15 
4 
18 
6 
2 
3 
*TNM classificatio1l oj ophthalmic IIfmOIll"S. U/ee Genem 1985. 
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/~f£~~~~~~;= iris: 1 cil.body: 6 
Figure J: Location oj Ihe ;lItra-oclIlllr (1III/OUrS, 
white area: iris. stippled area: Ci/i(lry b(}(ly. 
slriated area: equatorial choroid. black area: 
posterior choroid. diffuse (diJ.) ill lite choroid: 
olle melanoma. 
char. eq.: 3 
chor. post.: 18 
chor. dif.: 1 
retina 
sclera 
57 
No N-ras Mlltatiolls ill HIIlIlall V,'ea/ Me/allollla 
When frozen tissue sections were examined it appeared that 17 samples contained 100%, 8 
> 90%,3 > 75% and 1 50% tumour tissue. DNA was extracted from five sections of 5 
I'm thickness of each tumour, adjacent to the one used for histopathology. The extracted 
DNA was used as a template in the polymerase chain reaction (PCR) following the protocol 
as supplied by the manufacturer of Taq polymerase (Cetus, USA). The primers used for the 
amplification of the fragment comprising codons 12 and 13 were sense primer 5' 
CTGAGTACAAACTGGTGGTTGGT 3', antisense primer 5'CAAAGTGGTTCTG-
GATTAAGCT 3' and for amplification of codon 61: sense primer 5' AGTGGT-
TATAGACGGTGAAAC 3', antisense primer 5'GTGCTCATGTATTGGTCTCTCAT 3'. 
The amplified fragments were separated from the primers on a low melting point agarose 
gel, eluted from the gel and subjected to an asymmetric amplification using a 200-fold 
lower concentration of the antisense primer (Gyllenstein, 1989). This results in preferential 
synthesis of the sense strands. The single strand was subsequently isolated from an agarose 
gel and used as a template in sequencing reactions using the antisense primers and 
Sequenase (Promega). The reactions were performed as suggested by the supplier of the 
enzyme, with a 4 fold higher concentration of dideoxynucleotides and an elongation step of 
1 min. A plasmid with a mutation in codon 13 (GGT-GTT) served as a positive control, 
whereas normal DNA tissue served as a negative control. 
Examples of autoradiographs from sequencing gels are depicted in Figure 2. No 
deviations from the wild type sequence were found in codons 12 and 13 in these samples, 
nor in the other 27 melanomas. Similarly, in none of the 29 melanoma samples mutations 
in codon 61 could be observed. It is clear from our study, that uveal melanomas differ 
from the cutaneous melanomas with regard to the N-I'os mutation rate: N-ras mutations do 
not seem to play an important role in developing uveal melanoma. It is possible, however, 
that the other two ras genes may contain mutations. Shukla et aI., (1989) described K-ras 
mutations in 3 out of 22 patients with primary cutaneous melanomas. In this latter study no 
correlation was found between ras mutations and UV exposure. The patients described 
here, were all Caucasians, lived in the Netherlands and possessed mainly light irides. This 
is consistent with some of the risk factors mentioned for developing uveal melanoma. 
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Figure 2: Example oj afflorailiographJrom sequence gel. III rite left palle/rhe sequence oflhe amplified DNA/rom 
melanomas 5 alld 9 is ShOll'll for Ille area surrol/nding CO<iOIlS 12 aJUi 13. No(e the sequence sholl'll ;s that of the 
antisense straml. III the right pallel the sequence reactiollS were peljormed Oil amplified DNA from lite area 
surrounding CodOIi 61 ill meiOllOIIUl 5 awl 9 respecrl\'eiy (antisense strand). 
The cornea effectively filters out all UV radiation shorter than 295 nm. In children a 
substantial transmission of UV-A (320·400 nm.) and UV-B (290·320 nm.) occurs, which 
decreases with age (Lerman, 1980). Short UV wavelengths (UV-B) cause the formation of 
pyrimidine dimers in the DNA (Kraemer et a!., 1984). It is believed that the choroid and 
ciliary body are protected from UV exposure and also from a large portion of the more 
energetic wavelengths of the visible spectrum by the overlying retina and retinal pigment 
epithelium (Lerman, 1986). Thus we must conclude that although there is ample 
epidemiological evidence for a role of UV radiation as a risk factor in developing uveal 
melanoma, it is questionable if UV radiation is able to reach the choroid and ciliary body. 
In the contrary the iridic surface is not protected by the lens or by overlying tissue from 
UV A and B radiation. The well documented tendency for iris melanoma to occur in the 
inferior sector of the iris (Jacobiec et a!., 1981), where exposure to sunlight is presumably 
59 
No N~J'as Mutatiolls ill Humall U.'eal Melanoma 
the greatest, supports the view that the origin of these tumours is environmentally related. 
However, the incidence of iris melanoma is much smaller compared to those arising in the 
ciliary body or choroid. Another argument against the direct role of UV radiation in uveal 
melanoma might be that incidence and mortality rates for uveal melanoma are changing 
very little in Europe, North America, Japan and Australia (Strickland & Lee, 1981). This 
finding is in contrast to the rapid increasment of the incidence of cutaneous melanoma. 
Hersey et al. (1983) found an increase in T suppressor cells after solarium exposure and 
a relative decrease in T helper cells. Sunlight may work indirectly by inducing a systemic 
alteration in immunologic function (Stern, 1984). Although the role of these findings to 
human disease is not established, immunologic perturbations caused by exposure to sunlight 
may playa role in developing uveal melanoma, as part of multifactorial disease. 
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Summary 
The reactivity of 33 choroidal and ciliary body melanomas with monoclonal antibody Ki-
67, which recognizes a proliferation associated nuclear antigen, has been assessed and 
compared with clinicopathological parameters. In 23 cases, 8 Gy irradiation was given two 
days before enucleation. Nonirradiated melanomas had a significantly higher proliferation 
rate as defined by staining with monoclonal antibody Ki-67 as compared with irradiated 
tumors (p=O.OO7). Similarly, a strong relationship was found between pre-enucleation 
irradiation and low mitotic activity (p=O.OOI). There was no significant correlation 
between the presence of Ki-67 positive nuclei and histologic classification, largest tumor 
diameter, localization of the tumor, age, sex, scleral invasion, pigmentation, and 
lymphocytic infiltration. The relevance of Ki-67 immunohistochemistry for the assessment 
of the life prognosis of patients with uveal melanoma has to be studied prospectively. 
Inh'oduction 
The monoclonal antibody Ki-67 reacts with a DNA associated' antigen in the nuclei at all 
phases of the cell cycle except the resting phase.'" Immunocytochemical labeling with this 
antibody has been shown to correlate with generally accepted indices of cell proliferation 
such as autoradiography,' flow cytometry,' bromodeoxyuridine labeling index,' and 
thymidine labelling index' and therefore provides a simple and reliable means of rapidly 
evaluating the growth fraction of normal and neoplastic human cell popUlations. In some 
malignancies, '·11 it has been shown that Ki-67 labeling can serve as a prognostic parameter 
and recently its potential use as monitor for therapy in hormone-dependent human prostatic 
carcinoma has been described. 12 We have used immunostaining with monoclonal antibody 
Ki-67 in a series of ciliary body and choroidal melanomas to assess the proliferative index 
and to investigate the effect of pre-enucleation irradiation. This was done by comparison of 
eyes that had been irradiated with 2x 4 Gy electron beam irradiation on the last two days 
before enucleation and nonirradiated eyes with ciliary body and choroidal melanoma. We 
also studied the possible relationship between Ki-67 immunostaining and various 
conventional clinical and pathological prognostic parameters. 
64 
Chapter 6 
Matedals and Methods 
Patielll Selection 
Specimens were obtained from 24 patients treated in Rotterdam, and from nine patients 
treated in Amsterdam between January 1987 and October 1988. As part of another study, 
melanoma patients in Rotterdam receive from 1978, local radiotherapy in two fractions of 4 
Gy on the two days prior to enucleation. Thus, all eyes from Rotterdam, except one, were 
irradiated. The nine patients treated in Amsterdam were not irradiated. The enucleated eyes 
were transported immediately to the pathology department. After transillumination the eyes 
were cross-sectioned through the tumor and part of the tumor was snap frozen in OCT 
compound (Tissue-tek) and stored at _70°. The remainder of the eye was fixed in formalin 
and embedded in paraffin. 
Histopathologic Emll1inGtion 
Conventional histologic sections stained with hematoxylin-eosin were prepared from the 
paraffin-embedded tissue. We determined in these the following parameters: cell type 
(spindle, mixed or epithelioid type), mitotic rate, largest tumor diameter, scleral invasion 
(absent; slight, <25% of the scleral thickness; moderate, approximately 50%; deep, 
>75%; episcleral growth), pigmentation (absent; slight, 25%; moderate, approximately 
50%; heavy, >75%), and lymphocytic infiltration (absent, moderate or marked). Mitoses 
were counted in IS consecutive high power fields with a total magnification of x400. 
Immunohistochemistry 
Frozen sections of 6 I'm thickness were air dried and fixed for 10 minutes in acetone. 
Thereafter, slides were rinsed in phosphate-buffered saline (PBS, pH 7.4) and incubated 
with the monoclonal antibody Ki-67 (Dako Immunoglobulins Ltd, Copenhagen, Denmark). 
Slides were incubated with Ki-67 for 60 minutes at room temperature in PBS containing 
0.01 % gelatine and 0.1 % sodium azide. As second-step reagent, a peroxidase-conjugated 
polyclonal rabbit anti-mouse immunoglobulin serum was applied (Dakopatts, Denmark). 
Subsequently, slides were rinsed in PBS to remove the unbound portion of the second 
reagent. After a final thorough washing in PBS, antigen-antibody binding was visualized by 
incubation in an acetate buffer solution (pH 4.6) that contained 3-amino-9-ethylcarbazole, 
dimethyl formam ide, and hydrogen peroxide." Sections were counterstained with Mayer's 
hematoxylin for exactly IS seconds to obtain a discrete nuclear staining pattern without 
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obscuring the Ki-67 reactivity. Positive reactions produced a red color, making 
differentiation with brown/black endogenous melanin pigment possible. Of all samples 
analyzed immunohistochemicaUy with the Ki-67 antibody, consecutive frozen sections were 
stained routinely with hematoxylin-eosin for microscopic examination to evaluate the 
pathologic parameters. 
As a negative control, specimens were stained with the second-step reagent only. Frozen 
sections of two primary and one metastatic cutaneous melanomas served as a positive 
control. 
Assesslllelll of Ihe KI-67 Defined PI'OIij'erarive Acrivity 
Consecutive frozen hematoxylin-eosin sections of frozen tissue were examined by light 
microscopy. Counting of nuclei was performed at a magnification of x400. To facilitate the 
counting procedure a grid of measured dimensions was inserted in one of the ocular tubes. 
The number of nuclei was counted in three fields of an eye piece grid. Tissue sections 
stained with the antibody Ki-67 were examined and positive nuclei were counted in 15 eye 
piece grids and related to the amount of nuclei counted in the hematoxylin-eosin frozen 
section) thus measuring the percentage of positive cells in approximately 6000 nuclei in a 
random fashion: the number of high-power fields was randomly selected. CeU nuclei were 
considered to be positive if there was any nuclear staining present, regardless of the 
intensity and distribution within the nucleus. Counting of positive nuclei was repeated three 
times and averaged. Intra-observer variation varied between 0.02% and 0.25%. The Ki-67 
defined proliferative activity or Ki-67 score was determined by the quotient of Ki-67 
positive cells and total number of cells. 4 
Stalislieal Analysis 
The non-parametric Mann-Whitney U test was used to determine the relation between pre-
enucleation irradiation and Ki-67 proliferative activity. This test was also applied to study 
the relationship between pre-enucleation irradiation and level of mitotic activity. The 
KTiiskal-Wallis test was used to examine the relationship between Ki-67 proliferative 
activity and histologic classification. For the relationship between the Ki-67 score and 
clinicopathologic parameters the Spearman Rank Correlation test was used. 
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Results 
immunostaining with Ki-67 was observed in all tumors tested, but the percentage of 
positively staining cells varied from case to case. Staining with monoclonal antibody 
usually showed a speckled pattern in the nuclei (Figure I), but in some cases staining of the 
nuclear matrix was prominent. 
Figure 1: FroUII sectioll of all epithelioid cell-
type melanoma incubated wilh the mOlloclollal 
antibody Ki-67 (original magllificatioll, x150j. 
No/ice the speckled pattem oj Ki·67 
ilIIIIIIlllostail,blg. 
Only rarely, a weak cytoplasmic staining was seen. The percentage of Ki-67 positive cells 
in all melanomas ranged from 0.16% to 3.80%, and one with a high score of 18.30% 
(Table I). 
The Ki-67 score of irradiated and non-irradiated eyes differed significantly: A reduction in 
the Ki-67 score was observed after pre-enucleation irradiation (p= 0.007) (Figure 2). To 
quantitate this reduction, the natural logarithm of Ki-67 was taken because of its positive 
skewness and the unequal variance in the irradiated and the nonirradiated group. By 
comparing the mean logarithm of the Ki-67 score i~ both groups, it can be estimated that 
irradiation resulted into approximately a threefold reduction of the Ki-67-defined 
proliferative fraction. The 95 % confidence limits of this reduction are 1.3 and 9.8. 
Similarly, decreased mitotic rate was found after pre-enucleation irradiation (P= 0.001). A 
significant correlation was found between Ki-67 score and mitotic rate in the irradiated 
group, using the Spearman Rank Correlation test ('S = 0.58; P = 0.002) (Figure 3), but 
not in the nonirradiated group ('S = 0.12; P = 0.37) (Figure 3). 
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Table 1 ReslIlts of Ki-67 score alld C/illical and eathologic earameters 
Case Ki-67 Mitotic Cell LTD Irrc Locd Age Sex Sclere Pigm' Lym' 
no score rate TYQe' (mm)' (yrs) 
1 0.65 3 M 12 + P 40 F 4 2 1 
2 0.07 1 M 4 + C 38 M 2 4 1 
3 0.24 3 S 13 + P 56 M 5 2 1 
4 0.20 1 S 12 + P 60 M 2 2 2 
5 0.08 0 M 13 + C 54 M 2 4 1 
6 0.11 1 M 12 + P 59 F 2 4 1 
7 0.90 2 M 12 + P 38 F 3 2 1 
8 1.10 1 M 9 + P 81 M 4 2 1 
9 0.07 1 E 9 + P 58 F 4 2 1 
10 0.11 1 S 12 + E 76 F 1 4 1 
11 0.14 0 E 10 + P 67 M 1 2 1 
12 0.96 1 S 11 + P 50 F 1 3 2 
13 0.47 1 S 8 + P 68 F 1 2 1 
14 0.18 1 E 11 + A 58 F 1 2 3 
15 18.3 28 E 18 + E 69 M 2 2 1 
16 3.80 10 E 16 + P 74 M 4 2 1 
17 0.04 2 S 9 + P 64 F 3 2 1 
18 0.Q2 0 E 12 + P 74 F 2 4 1 
19 0.45 2 E 7 + P 63 M 2 2 1 
20 0.73 5 M 17 P 72 F 1 2 2 
21 0.32 7 S 10 + P 57 M 1 2 1 
22 0.27 4 M 18 + A 48 M 3 2 1 
23 0.38 2 E 13 + P 69 F 2 2 1 
24 0.16 1 M 12 + C 71 M 2 2 1 
25 3.08 7 M 6 P 66 F 1 4 1 
26 1.55 8 E 14 P 65 M 3 3 3 
27 0.52 3 M 6 C 66 F 1 2 1 
28 1.22 8 S 13 P 76 M 2 1 1 
29 0.16 3 S 12 P 57 F 1 2 1 
30 2.60 4 M 11 P 77 M 3 1 1 
31 0.67 9 S 9 P 75 M 5 2 1 
32 1.75 3 E 13 C 56 M 2 3 3 
33 0.83 8 M 18 P 64 F 4 3 3 
a: M = miwd; S = spindle: E = epithelioid cell type scared all paraffin embedded fiSSile. 
b: largest Illmor diameter. 
c: + = 8 Gy pre-ellllcfearioll il1urliafioJl; - = 110 irradiatiol/. 
d: loealioll: P = posterior; C = cilimy body; A = allier/or; E = equator, 
e: scleral iIlWl .... ioll: I = absellt; 2 = <25%,3 = 25-75%; 4 = > 75%,' 5 = episcleral groll'lh. 
f: pigmentation: J = abselll; 2 = <25%; 3 = 25-75%: 4 = > 75%. 
g: lymphocytic infi/fratioll: J = absellt; 2 = mor/erate,' 3 = marked. 
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Figure 2. Percellfage of Ki-67 posiliw nuclei ill a Figure 3. A statistically siglJijicallf correlatio/l (P < 
group o/palim/s, who receiwd 8 Gy pre-eJlucleatioll 0.001) was Jamul beMeell Ki·67 pos;tj~,;ty and mitotic 
irradiatioll (_) as compared to a grollp of pa/jellfs rate .• ,' pre-ellucleatioll irradiation (8 Gy). A " 110 pre-
who did 1101 receh'e pre-enucleation irradiatioll (,.,), elluciealioll irradiatioll. 
No significant correlation could be demonstrated between the Ki-67 score and largest tumor 
diameter (Figure 4), tumor localization or pigmentation, scleral invasion, and age and sex 
of the patient. Histologic classification obtained on frozen sections as well as on paraffin-
embedded tissue (Figure 5) also did not have a significant correlation with the Ki-67 score. 
In 12 cases, a discrepancy existed in histologic typing of the tumor between frozen sections 
and the paraffin-embedded tissue, which can be explained partly by sampling and partly by 
the unreliability of tumor typing on frozen sections. 
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Figure 4. Lack oj correlatioll between largest IUlllor Figure 5. Lack of correlatioll betweell Ki-67 positivity 
diameter (LID) alld 'he % of Ki-67 POSili\'e /luclei. alld rhe histological cell type, scored all pam.D;1I 
• : pre-elilieleatioli irradiatioll (8 Gy). <l : 110 pre- embedded risslle. • : pre-enucleation irradialioll (8 
enue/eatioll irradiatioll. Gy) . .d " 1/0 pre-€lIIlcleatioll irradiatioll. 
To compare our results with bromodeoxyuridine uptake in uveal melanomasJ we calculated 
Ihe mean Ki-67 counl in 32 high-power fields in nonirradialed melanomas. The mean counl 
was 128. 
The percenlage of Ki-67-positive nuclei of Ihe conlrol culaneous melanomas varied from 
1.4% (metastatic culaneous melanoma) 10 4.2%. 
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Comment 
Proliferation rates in uveal melanomas have been retrospectively studied by DNA flow 
cytometri' and by incorporation of bromodeoxyuridine. " Both methods have 
disadvantages: when flow cytometry is used, the proliferative index can only be assessed 
reliably in diploid tumors. The reported varying incidence of aneuploidy in uveal 
melanomas (between 4% and 77%"''') may therefore influence the proliferative index. In 
addition, flow cytometry cannot distinguish between tumor cells alone and tumor cells 
clumped with non tumor cells. In vivo or in vitro incorporation of the potentially mutagenic 
DNA bromodeoxyuridine is another frequently used technique to detect cells in the S-
phase. 17 A disadvantage of this technique may be that sufficient bromodeoxyuridine 
incorporation may not occur as a result of poor vascular supply to the tumor or due to 
limited tissue diffusion." Therefore, we have assessed the growth fraction of ocular 
melanomas using the monoclonal antibody Ki-67 on frozen sections, which is a simple and 
reliable method of rapidly evaluating the growth fraction of normal"-24 and neoplastic 
human cell populations."-" 
Under in vitro conditions, some authors have observed discrepancies between Ki-67 
labeling and bromodeoxyuridine incorporation. 33 Nevertheless, in a series of 20 human 
solid tumors a consistent ratio was found between Ki-67 labeling index (cycling cells/total 
tumor cells) and bromodeoxyuridine labeling index (S-phase cells/total tumor cells).' 
Comparing the mean Ki-67 count in non-irradiated uveal melanomas in 32 high power 
fields with the results of a previous study using bromodeoxyuridine uptake in non-irradiated 
uveal melanomas,15 the findings are in keeping with this ratio. 
In our study the Ki-67 score of nonirradiated uveal melanomas was low (i.e., < i % to 
3.08%) as compared to the Ki-67 score in primary malignant tumors eisewhere in the 
body I which varies from < 5 % to 65 %.8-12,22,24 Furthermore, our results indicate that the 
Ki-67 score of the nonirradiated choroidal melanomas is generally lower than the Ki-67 
score of nonirradiated primary cutaneous melanomas.3-4 Recently, a higher Ki-67 score was 
reported on five choroidal melanomas." These findings are not in keeping with the results 
using bromodeoxyuridine uptake in choroidal melanomas." Their discrepant findings can 
be attributed to differences in techniques and selection of patients. Unfortunately, no 
additional data were provided in their heterogenous series allowing their results for 
comparison. 
The question still remains if Ki-67 immunostaining is relevant for the assessment of 
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prognosis of patients with ocular melanomas. In our study, there was no correlation 
between Ki-67 score and conventional prognostic parameters such as histologic 
classification and largest tumor diameter. These results are similar to the findings for 
bromodeoxyuridine uptake in uveal melanomas." In this preliminary study, we did not 
attempt to assess clinical outcome because the follow-up time for the patients from whom 
we obtained frozen melanoma material was too short. The antigen recognized by Ki-67 
does not survive conventional fixation and thus is not suitable for retrospective studies on 
stored paraffin-embedded tissue specimens. It should be noted, however, that one of the 33 
examined patients died only 6 months after enucleation of disseminated choroidal 
melanoma (epithelioid cell type). Before enucleation, there was no clinical evidence of 
metastasis. The irradiated choroidal melanoma of this patient had the highest proliferative 
index (18.3%) in this study, which is comparable with the proliferative index reported for 
malignant tumors elsewhere in the body. It might be that selection of patients who are at 
high risk for tumor metastasis could be achieved by looking for a high proliferative index 
in addition to conventional prognostic parameters as histologic type, tumor size and mitotic 
rate. 
The prognostic significance of the Ki-67 staining remains to be proven. However, 
conventional counting of mitotic figures yields a poor reflection of the proliferative activity 
of a given tumor, because only a minor fraction of proliferating cells is in actual mitosis. 
The mitotic score may be unreliable, due to problems with identification of mitotic 
figures,36 variation in cell cycling time or to different handling of the tissue. 37 Nevertheless, 
in our study a good rank correlation ('S = 0.71; P < 0.001) was noted between the Ki-67 
score and mitotic rate in the irradiated group, similar to findings in mammary carcinoma,27 
but in contrast to findings in cervical carcinoma.3! 
In patients treated with 20 Gy in 5 fractions over 5 to 7 days before enucleation, pre-
enucleation radiotherapy has been shown to decrease the mitotic rate of choroidal 
melanomas to zero in 15/21 cases. 3S In our study, the mitotic rate was reduced to zero in 
only 3 of 23 cases. 
After more than 60 Gray equivalent (GyE) of helium ion charged-particle therapy, the 
proliferation rate measured by uptake of bromodeoxyuridine lVas zero in six of eight 
patients." A dose of 20 Gy pre-enucleation irradiation gave a 100-fold reduction of 
bromodeoxyuridine incorporation." The reduction of Ki-67 score in this study was 
approximately three fold after 8 Gy pre-enucleation dose, which is a small difference with 
respect to the variability of the KI-67 score in the irradiated group. 
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The lesser reduction of proliferative activity in our study can be explained by the much 
smaller radiation dose and the short interval between irradiation and enucleation. 
The aim of the low dose irradiation of 8 Gy was to reduce the risk of hematogenous 
metastases during the enucleation procedure" and was not meant to be curative. Whether 
radiation will only be effective when the number of cells synthesizing DNA is reduced to 
near zero is a point of discussion. 1.5 
In conclusion we demonstrated with KI-67 immunostaining a reduction of the proliferative 
activity of uveal melanomas after pre-enucleation irradiation. The proliferative activity of 
uveal melanomas was low in comparison to cutaneous melanomas34 and primary ma1ignant 
tumors elsewhere in the body. The relevance of Ki-67 immllnostaining for the life 
prognosis of patients with uveal melanomas remains to be established. 
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Summary 
For uveal melanoma it has been demonstrated that aneuploidy correlates with worse clinical 
outcome. However, a striking variation in incidence of aneuploidy is reported for uveal 
melanomas. Flow cytometry was used to study retrospectively DNA-ploidy of 132 uveal 
melanomas on paraffin-embedded material. Thirty-five patients received 2x 4 Gy doses of 
irradiation 24 and 48 hours before enucleation. Correlation between DNA-ploidy and his-
topathological grading, largest tumour diameter, tumour height, tumour location, scleral 
invasion, and TNlvf classification was assessed. Survival analysis methods were used to 
investigate the predictive value of these variables on clinical outcome. 
Of the tumours 37% were aneuploid and 63% were diploid. Intratumour ploidy 
heterogeneity was minimal (92% concordancy). A strong correlation (p=0.009) was found 
between DNA-ploidy aud cell type. No correlation was fouud between DNA-ploidy and 
other conventional prognostic parameters. 
Irradiated melanomas were significantly more aneuploid than non-irradiated tumours 
(p< 0.01). In survival analysis DNA-ploidy and the largest tumour diameter were 
significant in predicting metastatic outcome (p' 0.03 and 0.01 respectively); histologic cell 
type and tumour location were of borderline significance. 
Intl'oduction 
Ciliary body and choroidal melanomas are the Illost common primary intraocular 
malignancy in the adult. The estimated l5-year-survival rate after detection of the tumour 
is 53%.' The metastatic potential of uveal melanomas varies, depending on tumour cell 
type, largest tumour diameter (LTD), the standard deviation of the nucleolar area and the 
mean of the largest nucleoli. 2 New treatment modalities, including preoperative irradiation, 
have not substantially reduced the mortality rate of these tumours. ) 
In a variety of solid tumours, including cutaneous malignant melanoma4•j DNA flow 
cytometry has proved to be a useful and objective prognostic parameter in addition to 
conventional histopathological classification.6.7 For uveal melanoma, analysis of recent 
paraffin-embedded material has shown that aneuploidy correlates with poor prognosis,' but 
on older (> 15 years) archival paraffin-embedded material this was not confirmed.' The 
percentage of aneuploidy in different studies on uveal melanomas varies between 16%10 and 
78 %." In the largest study interpretable DNA histograms were obtained in 64 cases, from 
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which 36% was aneuploid.8 It has been shown that pre-enucleation irradiation reduces the 
proliferative activity in uveal melanomas,12,J3 Effects of pre-operative irradiation on 
tumour-ploidy have not been extensively investigated, however. In an attempt to resolve 
these inconsistencies, we have studied archival paraffin embedded tissue of 136 uveal 
melanoma of 13 years old maximum to test the predictive value of aneuploidy on clinical 
outcome. In the study material we included patients who had received 2x 4 Gy doses of 
irradiation before enucleation in order to reduce the risk of hacmatogenous metastases 
during the enucleation procedure. 14 
The aims of this study were 1) to investigate the incidence of aneuploidy in a large series of 
cases, 2) to assess intratumour heterogeneity, 3) to investigate the effect of pre-enucleation 
irradiation on DNA-ploidy, and 4) to investigate the effect of DNA-ploidy on clinical 
outcome. Estimation of S-phase fractions was not performed, because of unreliability of 
this method on paraffin embedded material." 
Materials and Methods 
From 1976 to 1989, 98 paraffin blocks and 5 frozen specimens from patients with 
choroidal and ciliary body melanomas were collected from the department of pathology, 
Erasmus University Rotterdam. Thirty-eight patients received 2x 4 Gy doses of irradiation 
before enucleation. Forty-three paraffin blocks from non-irradiated tumours from the same 
period were selected from the department of pathology, University of Nijmegen, totalling 
146 cases (Table I). Until 1993 adequate follow-up of 97 patients could be obtained by 
contacting the local ophthalmologist or the general physician. Follow-up data were 
requested and verified. Thirty-four patients died from tumour related causes, 50 patients 
were still alive and 13 patients died of other causes (Table 2). 
Three 50 I'm sections were cut from the paraffin blocks. Additional 7 lun sections were 
obtained from each side of the experimental material and stained with haematoxylin and 
eosin for histopathological evaluation. Eighty blocks contained more than 75 % tumour 
tissue and 66 blocks contained normal ocular tissue as well. Seven normal eyes without 
tumour were also examined. Of the 50 I'm sections, nuclear suspensions were processed by 
the method of Hedley et al." The paraffin was dissolved with two washes of xylene. All 
sections were rehydrated with two 10 minute washes in 100% alcohol, one wash with 96% 
alcohol, and two washes with 70% and 50% alcohol. The samples were rinsed with 
distilled water, and centrifuged for I 0 minutes at 800 g. The centrifuged tissue was 
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suspended in a test tube containing 0.5 % pepsin in 0.9% sodium chloride (pH 1.9 plus 
0.02 % azide) and incubated for I hour at 37°C with repeated vortexing, centrifuged at 
800 g. and subsequently the cells were resuspended in Hank's balanced salt solution 
containing ethidium-bromide (50 I'g/ml). The samples were filtered through a 40 I'm. 
nylon mesh filter. The stained samples were measured on a FACS Scan (Becton Dickinson, 
Sunnyvale, CAl. For each histogram 10' nuclei were analysed. In these paraffin-embedded 
tissues, artefactual low-staining debris and cell clumps tend to be present. Confounding 
effects of these signals were eliminated by setting a gate. 
Of 15 cases, a second paraffin block from a different area of the neoplasm was obtained to 
investigate intratumour heterogeneity. 
The five freshly obtained tumours had all been irradiated preoperatively. These samples 
were prepared and stained according to the method of Vindelav et al. J7 
Data AI/alysis 
The DNA-ploidy of the tumour sample was estimated by DNA index, which was calculated 
as the ratio between the median channel numbers of the first and the subsequent peaks in 
the sample. Tumour samples were accepted as diploid where there was a single 00/0 I 
peak. Samples with a coefficient of variation (CV) of the single diploid peak of more than 
9% were excluded. The CV was calculated as the full width of the 00/01 peak at half 
maximum divided by the mean channel number. In cases with multiple peaks, the 
popUlation with the lowest DNA content was assumed to represent the diploid population. 
In the samples from normal eyes the percentage 02M ranged from 3% to 6%. Therefore 
we defined a histogram as tetraploid if the second peak had a DNA index between 1.9 and 
2.1 and the fraction contained more than 8% of the nuclei measured. Samples with a DNA 
index of the second peak of more than 2.1 or less than 1.9 or with a first peak with a 
shoulder were defined as DNA aneuploid. 
Histopathological Gradillg 
The tumours were classified as spindle cell, epithelioid cell, or mixed cell type according to 
modified Callender's classification. Five other variables were measured: largest tumour 
diameter (LTD, <7 mm, 7-10 mm, 10-15 mm, > 15mm); tumour height «2 mm, 2-3 
mm, 3-5 mm, > 5 mm); tumour localisation (ciliary body, equator, posterior, diffuse) and 
scleral invasion (none, less than 50%, 75%, episcleral growth). In addition the tumours 
were classified according to the TNM system (WHO). 
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Statistical Analysis 
Cross tabulation together with the X' test were used to compare DNA-ploidy with the 6 
above described variables. For ordinal variables, the Cochran-Mantel-Haenszel trend 
version of the X', as implemented in SPSS, was performed. Distribution of (tumour 
related) survival is described by Kaplan-Meier curves, which were compared with the log 
rank test. Where appropriate a trend version of this test was performed. 
Results 
Seventy-two patients were male, and 74 were female. The mean age was 61.6 year. A total 
of 146 tumour samples were analysed. Fourteen cases were excluded, because of a high 
cv- three of whom had received pre-enucleation irradiation (Table I); in 12 of these 
follow-up was known (Table 2). On the remaining 132 cases possible correlations between 
the various parameters were analysed. Influence of histological cell type, LTD, tumour 
prominence, tumour localisation, scleral invasion, and TNM classification on survival was 
studied in 97 patients with adequate follow-up (Table 2), whereas the influence of DNA-
ploidy on survival was studied in 85 patients with adequate follow-up (Table 2). 
The total mean follow-up was 62 months. DNA-ploidy, and LTD were significant in 
predicting metastatic potential (p' 0.03, and 0.01 respectively) (Figs I and 2); histological 
cell type and tumour location were of borderline significance (p' 0.05). 
Table 1 Patielll Selection 
Total No. Excluded No. * Remaining No. 
2x 4 Gy. irr. 38 3 35 
no irradiation 108 II 97 
total 146 14 132 
.. Excluded because oj {l high coelJiciem oj \'(Iriatioll (eV). 
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Table 2 NUII/ber of PalielllS wilh Known Follow-up 
Total No. Excluded No. * 
Tumour related death 34 5 
Alive 50 5 
Non-tumour reI. death 13 2 
No follow-up 49 2 
total 146 14 
* Excluded becaltse of a high coejficie/lt of mriatioll (ey). 
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Figure 1: Kaplall-Meier sllrv;m/ cun'es ((uII/ollr related dealh) as a !ullctioll of DNA-ploidy ill a series of 85 
patients. 1: ul/ellploid melallomas; 2: dlj)loid melanomas; Tillie ill II/ollflis after enucleatioll. 
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Thirty-seven percent of the samples were aneuploid, including 17% of the tumours which 
were tetraploid; 63% were diploid (Table 3). A strong association (p< 0.0009) was found 
between DNA-ploidy and cell type (Table 3). This association remained significant after 
correction for LTD (p< 0.009) and TNM classification (p< 0.008) by stratification. 
No correlation was found between DNA-ploidy and LTD, tumour height, scleral invasion, 
tumour location, and TNM classification. 
A significant association was found between aneuploidy and pre-enucleation irradiation 
(p< 0.01) (Table 3). 
Normal eye tissue was diploid, as assessed on paraffin blocks of seven eyes without 
abnormalities. Of 12 patients two tumour samples were analysed: in 11 of these (92%) only 
one DNA peak was found. The five fresh tumours were all aneuploid, including one 
tumour of the epithelioid cell type. 
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Figure 2: Kaploll-Meier sw"im/ curves as (J Jllllctioll of Lmgest Tumour Diameter (LID) ill a series oj 97 
patients. 0: LTD: < 711/m; 1: LW: 7-10 mm: 2: LW: 10-15 mm; 3: LTD: > JS 111m. Time ill months after 
enucleatio1l. 
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Table 3 Crosslabulation DNA-ploidy and Clinicopathologic Features 
Aneuploid Diploid Tolal No 
Histological type 
Epithelioid 15 (60%) 10 (40%) 25 (100%) 
(31 %) (12%) (19%) 
Mixed 24 (42%) 33 (58%) 57 (100%) 
(50%) (39%) (43%) 
Spindle 9 (18%) 41 (82%) 50 (100%) 
(19%) (49%) (38%) 
Total 48 (37%) 84 (63%) 132 (100%) 
(100%) (100%) (100%) 
Pre-enucleated Irradiation 
no irradiation 29 (30%) 68 (70%) 97 (100%) 
(60%) (81 %) (73%) 
2x 4 Gy 19 (54%) 16 (46%) 35 (100%) 
irradiation (40%) (19%) (27%) 
Total 48 (37%) 84 (63%) 132 (100%) 
(100%) (100%) (100%) 
Discussion 
There is increasing evidence for a variety of neoplasms that DNA aneuploidy may correlate 
with poor prognosis,lS In primary cutaneous melanomas DNA aneuploidy has been shown 
to correlate with tumour thickness, incidence of recurrence, and survival..5 Studies in uveal 
melanoma demonstrated that an elevated DNA index (> 1.4) is strongly correlated with 
higher tumour related mortality.' We found aneuploidy in 37% of the cases, which is 
consistent with the findings of Meecham & Char.' The striking variation in incidence of 
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aneuploidy in earlier studies can partly be explained by the relatively small number of cases 
studied,o.1I and the use of fresh tissue.1O Another explanation may be the differences in the 
applied techniques, like assessing DNA content on older archival paraffin embedded 
specimens. In older material increased background noise from fragmented nuclei and 
cellular debris is important, and as sample age increases, such problems for DNA content 
seem to increase.19 Up to a period of 10 years the age of the block does not appear to 
influence the CV,'o because comparison of DNA-ploidy of fresh tissue samples with 
formalin-fixed paraffin embedded specimens in solid tumours showed a concordancy of 
87%." None the less, in the latter study near-diploid aneuploid peaks observed in 
histograms from fresh tissues were sometimes not apparent in histograms from paraffin .. 
embedded tissues, because of the higher CV for the latter samples. Another problem in 
paraffin-embedded specimens is that, if both diploid and near-diploid aneuploid peaks are 
present, it is difficult to determine which peak is diploid. To obviate this particular problem 
in 66 cases we measured a mixture of nuclei from a paraffin block of normal tissue and 
tumour tissue from the same specimen as recommended by Schutte et al. 22 
A further explanation for the variable percentage of aneuploid cases reported is tumour 
heterogeneity. In a small tumour sample an aneuploid subpopulation of cells might remain 
undetected. However, in the cases in which we could study two blocks, 92% was 
concordant. We found the predictive value of aneuploidy for survival to be significant (p< 
0.03), contrasting with a study on older formalin-fixed paraffin-embedded specimens.' Our 
findings indicate that specimens can be used for flow cytometry at least up to 10 years after 
preparation. 
Although simplification of the original Callender classification has improved histologic 
correlation with malignancy, interobserver error can be large.23 Subsequently, a more 
quantitative system was developed to estimate subjectively the percentage of epithelioid 
cells in each tumour," however still relying on subjective judgement. Therefore methods 
have been developed to measure more objective features. One of these methods is 
determining DNA ploidy. We have demonstrated that archival paraffin-embedded material 
can be used for flow cytometry analysis to predict clinical outcome. We found that 
aneuploidy in uveal melanomas strongly correlates with epithelioid cell type, none the less, 
aneuploidy appears to have a better predictive value for prognosis than subjective 
histopathological classification. In our study we found that cell type and tumour location 
were of borderline significance in predicting clinical outcome. This is in contrast to earlier 
reports on prognostic factors in uveal melanoma," but in agreement with recent findings of 
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Folberg et a!. 26 
Interestingly, we found irradiated melanomas to be significantly more often aneuploid than 
non-irradiated melanomas. Radiation induces mitotic delay and both numerical and 
structural chromosome aberrations. 27 It is conceivable that during cell cycle progression 
alterations of chromatin condensation and DNA fluorochrome labelling lead to DNA 
damage which, in flow cytometry, may give rise to the appearance of pseudo-aneuploid cell 
populations." Numerical chromosomal aberrations may give rise to near diploid or near 
tetraploid histograms. However, the decline in radiation induced aberrations in the initial 
24 hours is rapid, presumably as a result of DNA repair." In vitro studies on a K-1735 
melanoma cell line exposed to 7 Gy. X-irradiation revealed that increase in karyotype 
diversity generated by radiation, when nonlethal, may accelerate tumour progression." 
Unfortunately no paraffin tissue was left to study the relationship between DNA aneuploidy 
and chromosomal aberrations in irradiated melanomas. 
We demonstrated a strong correlation (p< 0.009) between aneuploidy and epithelioid cell 
type. Other studies indicated a similar correlation, but were too small to draw statistical 
conclusions. IO•31 Aneuploidy may reflect a genetically more unstable popUlation with an 
enhanced ability to metastasize. 
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Summary 
Neoplasia can be defined as deregulated tissue homeostasis due to an imbalance between 
proliferation and apoptosis. Many genes are involved in the maintenance of tissue 
homeostasis e.g. the c-myc oncoprotein, which is an important regulator of cell 
proliferation and BcI-2 protein, which is involved in the regulation of apoptosis. We 
studied retrospectively indices of proliferation, such as mitotic count and the Mib-I index, 
on 51 uveal melanomas and compared their prognostic significance with established 
indicators of prognosis such as cell type and tumor size. Along the same line we 
investigated the expression of the regulating proteins c-myc and BcI-2. Of all parameters 
tested, the largest tumor diameter (LTD) and mitotic count were most strongly associated 
with tumor-related death (p<O.OOI and p= 0.005 respectively). In addition, cell type, the 
presence of epithelioid cells, the Mib-l index, and the percentage of cytoplasmic c-myc 
positive cells were significant predictive factors. Multivariate analysis showed that the Mib-
I index, LTD and the percentage of cytoplasmic c-myc positive cells were independent 
prognostic parameters. BcI-2 expression did not correlate with clinical outcome. The Mib-I 
index correlated with the presence of epithelioid cells (p< 0.03), the presence of apoptotic 
bodies (p< 0.001) and c-myc. A strong inverse relationship was found between (nuclear 
and cytoplasmic) c-myc and Bcl-2 (p<0.00004 and p<0.006 respectively), suggesting that 
Bcl-2 cooperates with c-myc to immortalize uveal melanoma cells. 
Introduction 
The maintenance of homeostasis in normal tissue can be viewed as a tightly regulated 
balance between cell production and cell death.' Neoplasia can arise when tissue 
homeostasis is deregulated. Most of the knowledge concerning oncogenic events has 
concentrated on mechanisms of increased cell growth. However, decreased cell death also 
would result in an expansion of the cell mass.' Cells can die either by necrosis (inactively) 
or by apoptosis (actively). Individual cell disintegration is a constant finding in malignant 
neoplastic tissue and these dying or dead cells, morphologically characterized by volume 
contraction and nuclear condensation have been called apoptotic. 2 Monoclonal antibodies 
(MAbs) against proteins involved in the regulation of cell proliferation and death can be 
used to visualize the dynamics of tissue homeostasis. The Bcl-2 protein blocks apoptosis 
and thus prolongs cell survival. In human fetal tissues Bcl-2 appears to be involved in 
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tissue homeostasis as well as morphogenesis.' Only few reports concerning Bcl-2 
expression in non-hematopoietic malignancy have been published ,4-7 including cutaneous 
melanoma.' The c-myc protein is involved in the control of cell proliferation, but is also a 
potent inducer of apoptosis.' C-myc expression is frequently deregulated in neoplasms and 
is often implicated in their genesis. 1O The c-myc gene is located on chromosome 8q24.1; 
chromosomal abnormalities involving chromosome 8q have been specifically associated 
with uveal melanoma. II It has been found that staining for c-myc protein correlates with 
proliferative index in diploid uveal melanomas, supporting the hypothesis that c-myc 
protein is involved in cellular proliferation,I2 Proliferative indices may provide information 
independent of other histological and clinical prognostic variables. 13 The MAb Mib-1 
recognizes the Ki-67 antigen, which is expressed by proliferating cells and can be used on 
formaldehyde fixed paraffin sections. 14 
The purpose of this study was to determine whether or not the expression of c-myc, Mib-1, 
Bcl-2 and the mitotic rate in uveal melanomas have independent prognostic significance in 
comparison to ceB type and tumor size. Furthermore we investigated the associations 
between the proteins involved in the regulation of cell proliferation and death. 
Materials and Methods 
Hisl%gic Specimens 
In order to correlate immunohistochemical findings with prognosis, a retrospective analysis 
of 51 formalin fixed paraffin-embedded uveal melanomas was undertaken. From 1973 to 
1987 consecutive cases were entered in the study on the basis of availability of adequate 
histologic material. Follow-up data were obtained by contacting the local ophthalmologist 
and/or the general practitioner, and these data were reviewed in order to define tumor-
related death or death due to other causes. 
In order to test the antibody specificity we used frozen tissue from one of the patients 
included in this series and a cell line (OMM-I), obtained from metastatic uveal melanoma 
tissue. IS A colon carcinoma and a breast carcinoma served as a control for c-myc. 
Paraffin sections were cut at 5 to 6 IJln and stained with hematoxylin-eosin. In these 
sections we determined the following parameters: largest tumor diameter (LTD) (dO mm, 
10-15 mm, > 15 mm), cell type, mitotic rate and the presence of apoptotic bodies. The 
tumors were histologically classified in two groups: I) according to cell type, using the 
three categories of the modified Callender classification (spindle cell, mixed cell and 
91 
Apoptosis alld Proliferatioll ill Uveal Melalloma 
epithelioid cell type)16 and 2) according to the presence or absence of any epithelioid cells 
(spindle cell melanoma versus a combination of mixed cell type and epithelioid tumors).17 
Mitoses were counted in 15 high power fields (HPF) with a total magnification of x400, 
using an eye piece grid. This was repeated three times and the number of mitoses was 
averaged. Apoptotic bodies were recognized by volume contraction and nuclear 
condensation of tumor cells.' Using light microscopy, uncertainties in defining apoptotic 
bodies remain, therefore we did not use an index for apoptotic bodies,' but scored for the 
presence or absence of apoptosis. 
Areas with tissue necrosis were excluded from the counting. 
]mmullohistochemisllY 
Formalin fixed and paraffin embedded 5 I'm sections were mounted on 
aminopropyltriethoxysilane (APES, Sigma, St Louis, USA) coated glass slides and dried 
overnight at 3rC. After deparaffinizing and rehydrating, the slides were placed in 0.01 M 
citrate buffer and antigen retrieval was performed by microwave irradiation (Bio-Rad) for 
2x 5 min. The slides were pre-incubated with normal goat serum in a dilution of I: 10 for 
15 minutes. 
The following specific antibodies were used: 
1) The MAb raised against the C-terminal peptide (9EIO) (amino acids 408 through 439) of 
the human c-myc protein (Oncogene Science Inc. New York, USA) was used in a dilution 
of 1: 1600 and incubated overnight. The slides were incubated for 30 minutes at room 
temperature (RT) with biotinylated multilink immunoglobulin (Ig, Biogenex) in a dilution 
of 1:75, in phosphate-buffered saline (PBS) with 5% BSA. After washing in PBSlTween 
0.5 % the slides were incubated with the streptavidin-biotin-peroxidase complex (Biogenex) 
in a dilution of 1:50. The alkaline phosphatase anti-alkaline phosphatase (APAAP) 
technique was used as detection system with fast red as chromogen. As specificity control, 
sections were incubated with antibody preincubated overnight with 10 I'g/ml excess of the 
peptide (Oncogene Science, New York, USA). 2) The MAb MIB-I, reacting with the 
proliferation associated antigen Ki-67 (Dianova-Immunotech, Hamburg, Germany) was 
used in a dilution of 1:200, in an overnight incubation protocol at 4°C. 
3) The MAb specific for Bcl-2 oncoprotein (clone 124) was obtained from DakopaUs 
(Glostrup, Denmark) and used in a dilution of I :60. Slides were incubated for 60 minutes 
atRT. 
After incubation with MAbs Mib-I and Bcl-2, the slides were incubated for 30 minutes at 
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RT with biotinylated goat-anti mouse Ig (Dakopatts) in a dilution of I :400, in PBS with 
2 % human serum and normal goat serum. After washing in PBS, the slides were incubated 
with the streptavidin-biotin-peroxidase complex (DakopaUs) in a dilution of I :200. The 
peroxidase was visualized using hydrogen peroxide in N-N-dimethylformamide with 3 
amino-9 ethylcarbazole dimethylformamide as chromogenic substrate. 
As a negative control, specimens were stained following the same incubation protocol 
without use of the primary MAbs. All sections were counterstained with Mayer's 
hematoxylin and mounted with glycerin/gelatin. 
As positive control for c-myc, BcI-2 and Mib-I sections of a breast carcinoma, normal 
thymus and adenocarcinoma of the prostate, respectively were used. In addition cytospin 
preparations of OMM-I cells were used as positive control for Bcl-2 and c-myc. 
Assessmem of Results 
Immunohistochemical results were evaluated without access to the follow-up data. The 
Mib-I score was determined as the percentage of Mib-I positive cells relative to the total 
number of cells per HPF. Cell nuclei were considered to be positive if there was any 
nuclear staining present, regardless of the intensity and distribution .within the nucleus. C-
myc and Bcl-2 scores were semi-quantitatively determined as percentage of cytoplasmic or 
positive cells 0, 1-25%, 25-50%, 50-75%, 75-100%. Nuclear staining of c-myc was scored 
similarly, with an additional score for focal «5%) staining. 
Westel'll B/otlil1g 
The specificity of the c-myc and BcI-2 monoclonal antibodies for use in 
immunohistochemistry was determined by Western blotting of a total protein extract from 
frozen uveal melanoma tissue and OMM-I cultured cells. Frozen tissue from a colon-and a 
breast-carcinoma served as control for c-myc. The frozen tissue was homogenized in a 
buffer containing a mix of proteinase inhibitors. OMM-I cells were harvested using a cell 
scraper, sonicated, and freeze/thawed. The homogenate was boiled in denaturation buffer 
(0,1 % dithiothreitol; I % sodium dodecylsulphate; 10% sucrose; Tris/HCL) for 5 minutes. 
The proteins were loaded on a SDS/Polyacrylamide-gel (12%). The gel was blotted 
overnight (0.2 A; 33 V, 4°C) on Immobilon P (Millipore) and incubated at RT with 2% 
BSAlO, I % Tween-20/PBS and subsequently with I % goat serum in 0, I % Tween-20/PBS 
for 20 minutes. The dilution used for BcI-2 and C-myc was I :3000 and I: 100, 
respectively. Incubation was performed at RT for 2 hours. Peroxidase-conjugated rabbit-
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anti-mouse Ig (DAKO) was used as a second antibody in a dilution of 1: 10.000. The 
peroxidase was visualized by the enhanced chemiluminescence method (Amersham). 
Between each incubation step the blots were rinsed five times with PBS/O, I % Tween-20 
for 112 hour. 
Statistical Allalysis 
Spearman's correlation coefficient was used to determine the associations between the 
variables mitotic rate, presence of apoptotic bodies, Mib-I score, the percentage of c-myc 
(cytoplasmic or nuclear) and Bcl-2 positive cells, LTD, cell type and presence of 
epithelioid cells. 
The Kruskal-Wallis test was used to determine the relation between the variables cell type, 
Mib-I score and the percentage of positive c-myc (cytoplasmic or nuclear) and Bcl-2 
positive cells. The Mann-Whitney-U-Wilcoxon test was used to evaluate the association 
between the presence of epithelioid cells, the Mib-I score and the percentage of c-myc 
(cytoplasmic or nuclear) and Bcl-2 positive cells. 
The logranktest and Cox proportional hazards analysis were used as univariate and 
multivariate regression analysis to assess the influence of different potential prognostic 
factors on survival. A p valne <0.05 was considered significant. 
Results 
Clinicopathological Parameters 
The mean age at diagnosis was 59.8 years. Thirty-two patients were male, 19 female. 
Twenty-three patients died of tumor related death, 9 died of other causes, 13 were still 
alive, and 6 were lost to follow-up. The tolal mean follow-up was 83.9 months. 
Twenty tumors were classified as spindle cell type, 19 as mixed cell type and 12 as 
epithelioid cell type: in 32 of 51 tumors epithelioid cells were present. Five tumors were 
small « 10 mm), 24 were 10-15 mm, and 22 were large (> 15 mm). 
The mitotic rate was low «2 mitoses per 15 HPF) in 39 of 51 tumors. In 12 tumors a 
mitotic rate of >2 per 15 HPF was noted, 6 of these patients died of tumor-related death. 
Apoptotic bodies were relatively abundant in one tumor (Figure la) and could only 
sporadically be observed in 10 other tumors. 
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Allfibody Specijiciry 
OMM-l cells and the frozen tissue displayed a weak reactivity for c-myc and strong 
reactivity for Bcl-2. The anti c-myc antibody recognized a protein in OMM-l cells (Figure 
2), uveal melanoma cells, and in the carcinomas of approximately 40 kD. In the 
carcinomas, in addition a specific doublet was noted at 65 kD. In the slides, which were 
pre-incubated with the peptide antigen, the specific reaction with the c-myc antibody was 
eliminated. 
The anti-Bcl-2 antibody bound a protein in OMM-l cells with an apparent molecular 
weight of 25 kD (Figure 2), which is in agreement with the described molecular weight of 
Bcl-2 in other tumors.' 
Immullohistochemisny 
In 15 tumors the Mib-l score was> 1,8% (Figure Ib), eight patients in this group died of 
tumor-related death. 
In one tumor c-myc staining could not be reliably assessed. In 16 (33%) both nuclear and 
cytoplasmic staining was noted (Figure Ic); in 40 (78%) only cytoplasmic staining. The 
distribution of the scores is reflected in Figure 3. As internal positive control in the same 
sections non-tumor ocular tissue staining was noted in the photoreceptor inner segments of 
the retina. 
In 49 melanomas cytoplasmic bcl-2 staining was found (Figure Id), two were negative. 
The distribution of the scores is reflected in Figure 3. In non-tumor ocular tissue staining 
of Bcl-2 was noted as an internal positive control in normal choroidal melanocytes, the 
retinal pigment epithelium, the non-pigmented epithelium of the ciliary body, tumor 
infiltrating lymphocytes, in the MUller cells, the plexiform layers of the retina and the glial 
cells of the optic nerve. 
In the one tumor with abundant apoptotic bodies Bcl-2 expression was low, whereas c-myc 
(nuclear and cytoplasmic) expression and the proliferative activity were high (19 mitoses 
per 15 HPF, Mib-I score: 2.68%). 
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Statistical Analysis 
The Mib-l score correlated significantly with mitotic rate (p< 0.003), the presence of 
apoptotic bodies (p< 0.001) and the presence of epithelioid cells (p< 0.037). The mitotic 
rate correlated significantly with cell type (p<0.04). 
A strong inverse relationship was found between nuclear! cytoplasmic c-myc positive cells 
and BcI-2 expression (p <0.00004! p <0.006 respectively) (Figure 3). The percentage of c-
myc cytoplasmic positive cells correlated with the Mib-I index (p< 0.01), however, 
nuclear c-myc protein staining did correlate significantly with BcI-2 staining (p<0.09). 
The logrank test revealed a significant correlation of survival with cell type (p < 0.05), the 
presence of epithelioid cells (p< 0.05), LTD (p< 0.001), mitotic rate (p< 0.005), the 
Mib-I score (p < 0.04), and the % of c-myc cytoplasmic positive cells (p < 0.05), but not 
with BcI-2 staining. 
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In the multivariate analysis with the Cox proportional hazard model, the correlation of 
LTD, the Mib-l index and % of c-myc positive cells with survival remained significant 
after correcting for the influence of other investigated parameters. 
Discussion 
We have demonstrated that the percentage of c-myc cytoplasmic positive cells is 
significantly correlated with the Mib-l index, which is in line with the involvement of c-
myc in maintaining cell proliferation. In agreement with the findings on pc-to 
(proliferating cell nuclear antigen)" staining but in contrast to earlier findings with Ki-67 
defined proliferative activity," we found the mitotic rate and the Mib-l score to be 
correlated. The latter discrepancy is probably due to a difference in the methods used to 
define the number of tumor cells per HPF, which affects the Mib-l score. We also showed 
specific c-myc staining in uveal melanoma cells. The molecular weight for c-myc we found 
in immunoblots of uveal melanoma is less than the molecular weight described for c-myc in 
other tumors.20 However, it has been demonstrated that two proteins of 32 kD and 58kD 
detected in extracts of human cells are antigenically related to the synthetic peptides, to 
which the antibody was raised. 21 Furthermore it has been shown that clone 9EtO reacts by 
immunoprecipitation and immunoblotting with human c-myc encoded 67 kD and its 
cleavage products. 22 The use of a neutralized antibody excluded nonspecific effects. 
Staining for c-myc protein was found in both the nucleus and the cytoplasm. This was 
earlier reported by Royds et a!. 12 but in a higher percentage of lesions than in our series. 
However, all their melanomas were of the mixed and epithelioid cell type, and classified as 
large tumors (> 15 mm), whereas our study contained 39% spindle cell melanomas and 
57 % small and medium sized tumors. The cytoplasmic localization of c-myc was 
unexpected. The c-myc gene encodes two nuclear phosphoproteins.IO,20 It has been 
suggested that newly-synthesized myc protein is retained in the polyribosomes. Upon 
activation of this system, c-myc would be released to the nucleus, where it has been shown 
to bind both to specific and relatively non-specific DNA sequences, perhaps influencing 
DNA' replication." Aberrant expression of c-myc protein may both result from and 
contribute to deregulation of cell proliferation, with altered nuclear import and processing 
of c-myc leading to cytoplasmic accumulation of the protein. 
Furthermore, we found a strong inverse relationship between c-myc (nuclear as well as 
cytoplasmic) and BcI-2 immunoreactivity. Expression of c-myc is strongly implicated in the 
98 
Chapter 8 
control of cell growth and proliferation: c-myc and other cell cycle related genes play an 
important role in the GO-GUS phase transition." In addition c-myc recently proved to be a 
potent inducer of apoptosis when expressed in the absence of serum or growth factors.'·" 
These opposing roles of c-myc in cell growth and cell death are modified by Bcl-2: it has 
been demonstrated that Bcl-2 prevents apoptotic cell death induced by c-myc, providing a 
mechanism whereby cells can express c-myc without undergoing apoptosis.2~" We found 
apoptosis not to be a prominent feature in uveal melanomas. 
Fibroblasts which express c-myc do not undergo growth arrest in low serum concentrations 
as do wild-type fibroblasts, but undergo apoptosis." It has been shown that expression of 
Bcl-2 protein specifically abrogates c-myc-induced apoptosis without affecting c-myc 
mitogenic function. 30 This may explain the synergism between c-myc and Bcl-2 in certain 
tumors. 17 
The most important findings in this study are that in addition to LTD, the Mib-I index and 
the percentage of cytoplasmic c-myc positive cells are useful independent prognostic 
parameters for ciliary body and choroidal melanomas. This has been suggested in earlier 
studies of Ki-67 on frozen sections of uveal melanomas,19 and in a recent study of PC-IO" 
and c-myc on wax embedded uveal melanomas." BcI-2 did not appear to be of prognostic 
significance. 
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Summary 
In tumor development, proteases like plasminogen activators (PAs) play a role in 
degradation of the extracellular matrix and other tissue barriers. Recently, we demonstrated 
that plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of 
cutaneous melanocytic tumor progression. In this study we investigated the expression and 
distribution of the various components of the PA system and the presence of PA enzyme 
activity in 45 freshly frozen primary uveal melanomas with known follow-up (14 spindle 
and 31 non-spindle-type) and in metastases (n=5). Tissue-type PA (I-PA) was found in 
endothelium of blood vessels and in tumor cells in almost all lesions. t-PA was markedly 
present at the invasive front (towards the sclera and Bruch's membrane), but no correlation 
with tumor related death could be established. Urokinase PA (u-PA) was expressed focally, 
only by 5 non-spindle cell melanomas and in all metastases. u-PA expression correlated 
with occurrence of metastasis. u-PA receptor (u-PAR) was present in one third of all 
lesions examined. Plasminogen activator inhibitors (PAI-l and PAI-2) were only found 
focally in approximately ten percent of the lesions. In all metastases staining of t-PA, u-PA 
and PAl was observed. 
We conclude that in uveal melanoma, u-PA expression may be associated with metastatic 
disease and accordingly with poor prognosis. Further research on a large group of tumors 
with known follow-up is needed to establish whether u-PA positivity is of additional 
prognostic value in uveal melanoma. 
Introduction 
To migrate from the primary tnmor into blood vessels and to home and grow at a distant 
site in the body, tumor cells need an extensive repertoire of proteins (I). l,'or migration 
through and breakdown of tissue barriers, proteases are required (2). An important 
proteolytic system involved in tumor progression comprises the proteins of the plasminogen 
activator system (3,4). The two known plasminogen activators (PAs) are tissue-type 
plasminogen activator (t-PA) and urokinase type plasminogen activator (u-PA). PA activity 
can be inhibited by specific PA inhibitors, PAI-l and PAI-2 (5). u-PA activity can be 
focused at the cell surface by binding to its receptor (u-PAR). Also, u-PA activity can be 
enhanced by binding to the receptor, as the conversion of the inactive pro-u-PA to active· 
u-PA is facilitated on the cell surface (6,7). Furthermore, by rapid internalization of u-PAR 
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saturated with u-PA:PAI-I and recycling of u-PAR, the availability of u-PAR for u-PA 
binding is ensured (8-10). The saturation of the u-PAR is either autoerine or paracrine (lI-
B). 
The actual involvement of PAs in tumor cell migration and metastasis formation has been 
shown in several model systems (14-16). Elevated levels of u-PA, u-PAR and PAl in 
human malignant tumor tissue relative to the benign precursor lesion or normal tissue have 
been reported for tumors of diverse origin (17-22). Furthermore, u-PA content has shown 
to be a valuable prognostic marker for mammary carcinoma (19,23). The role of t-PA in 
tumor progression however, is morc ambiguous. Lower levels of t-PA in tumors compared 
to benign lesions have been reported for tumors of the mammary gland (24) and the ovary 
(21). Regarding cutaneous melanoma, some reports indicate a high expression of t-PA in 
melanoma cell lines (16,25,26) and cutaneous melanoma lesions (25,26). 
We recently demonstrated both in a nude mouse model (16) and in fresh human cutaneous 
melanocytic lesions (22) a possible role for the PA system in melanoma tumor progression. 
u-PA and PAl expression was related with high metastatic capacity of melanoma cell lines 
in nude mice (16). This was reflected in the in vivo situation in fresh human melanocytic 
lesions: u-PA, PAl-I and PAI-2 but also t-PA and u-PAR emerge in late stages of 
cutaneous melanocytic tumor progression (22). 
In this study, we extend our investigation on the involvement of the PA system in 
melanoma tumor progression to melanoma of the uvea. Melanoma of the uvea is the most 
common primary intraocular malignancy in adults (27). Several factors have been found to 
influence the prognosis. These include tumor cell type (spindle cell type has a better 
prognosis than non-spindle cell type) and tumor diameter. Uveal melanoma differs from 
cutaneous melanoma in several aspects. Uveal melanomas spread hematogenously, 
preferentially to the liver, whereas cutaneous melanomas primarily metastasize 
lymphogenic. The estimated 5-year-survival rate for uveal melanoma is 75 % (28) and 
comparable with cutaneous melanoma (29). The aim of this study was to investigate the 
expression of the different components of the PA system in uveal melanoma. The presence 
of these proteins was studied on fresh human lesions of primary uveal melanoma and 
metastases of uveal melanoma using immunohistochemistry and in situ zymography. 
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Material and Methods 
TisslIe Specimells 
Specimen from primary uveal melanomas were obtained from 45 patients treated at the 
Department of Ophthalmology, Erasmus University Rotterdam, The Netherlands, between 
1987 and 1992. The enucleated eyes were transported on melting ice to the Department of 
Pathology. After transillumination, the eyes were cross-sectioned through the tumor and 
part of the tumor was snap frozen in OCT compound (Tissue-tek) and stored at -70 °c. 
The remainder of the eye was fixed in formalin and embedded in paraffin. 
Five uveal melanoma metastases were from three patients from the skin (n=2), the heart 
(n =2) and from the liver (n = I). From 4 metastases, no primary tumor was available. 
From one metastasis, the primary tumor was also included in this study. Metastases were 
from the Departments of Pathology of Nijmegen (n =4) and Rotterdam (n= I). 
Antibodies 
Rabbit anti-human t-PA and u-PA polyclonal antibodies were from the Gaubius Institute, 
Leiden, The Netherlands and have been used in earlier studies (16,22). Monoclonal 
antibodies against human u-PAR (# 3936) and human PAI-I (# 380) were purchased from 
American Diagnostica Inc., Greenwich CT, USA. The rabbit and goat polyclonal 
antibodies against human PAI-2 were a generous gift from E. Schiiler, Behring Werke AG, 
Marburg, Germany. All antibodies against components of the PA system were used in a 
previous study (22). In that study, using parallel sections for mRNA in situ hybridization, 
we established with these antibodies that cells producing the mRNA also contained the 
protein. Detection of the melanocytic differentiation marker gp-lOO with monoclonal 
antibody NKI-beteb (30) was used to establish the melanocytic origin of the tumors. 
lmmlllloilislocilemisllY 
For immunohistochemistry, 4 .urn cryostat sections were air-dried overnight at room 
temperature and stored at -80 °C until use. Dilutions of the antibodies and staining 
procedure were as used before (22). Stainings with monoclonal antibodies were developed 
with an ABC technique, polyclonal antibodies with peroxidase labeled anti-rabbit or anti-
goat secondary antibody. Bound antibodies were visualized by using 3-amino-9-ethylcar-
bazole as a substrate for peroxidase. After counterstaining the nuclei with Papanicolaou's 
Harris solution, sections were mounted with Kaisers glycerin (Merck, Darmstadt, 
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Germany). A lymph node metastasis from a cutaneous melanoma, previously found to 
express abundant u-PA, u-PAR and PAl-l protein, was used as a positive control; for t-PA 
the staining of blood vessels served as internal control and for PAI-2, staining of sections 
from fresh human placenta served as positive control. An incubation where the first 
antibody was omitted, served as a negative control. 
Score 
For each section, the percentage of positive melanocytic cells was estimated. Each section 
was assigned to one of the following categories: 0%, 1-5%, 5-25% and 25~100% 
positivity. Notes were taken of other staining components (fibroblast-like cells, 
extracellular matrix) among the melanocytic areas. Sections were scored independently by 
two observers (C.M. M., M.R. v. B.). Discrepancies were found in only a few cases. 
These cases were re-evaluated jointly until agreement was reached. 
II/ Silll ZYlllography 
The technique has been described in great detail by Sappino et al. (31) an~·De Vries et aI. 
(22). Briefly, 8 I'm cryostat sections were covered with an overlay mixture containing dry 
milk, plasminogen and agar. At spots where plasminogen activation occurs, lysis of the gel 
takes place, making the gel transluminent. Addition to the gel of polyclonal antibodies 
against t-PA or u-PA allows discrimination between the two plasminogen activators. In 
addition, amiloride also inhibits u-PA specifically. With each incubation session, xenograft 
lesions of the human melanoma cell lines BLM or MV3, known to express abundant u-PA 
and hardly any t-PA (16), were included as positive control. 
Results 
C/il/ico-Pathological Data 
Histopathological diagnosis was obtained on paraffin embedded tissues. Cell type of the 
tumors was classified with the presence or absence of any epithelioid cells as criterium: 
spindle (n=14, tumors containing only spindle cells) or non-spindle (n=3l, a combination 
of mixed and purely epithelioid tumors) (32). As other variables we measured: largest 
tumor diameter; tumor height, presence of episcleral growth, and presence of vascular 
invasion. AU but two specimens examined, contained more than 50% viable tumor cells. 
Follow-up was available from all patients included in this study; from one of these patients 
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a freshly frozen subcutaneous metastatic lesion was obtained. Eight out of 45 patient died 
due to tumor related death (fRD), 3 died of other causes. The total mean follow-up was 
34.7 months. 
In 10 eyes extrascleral growth was noted; 3 melanomas showed obvious vascular ingrowth. 
immlilloilisiOcilemistly 
All primary tumors and metastases stained with NKI-beteb (30), recognizing gp-100, a 
melanocytic differentiation marker (not shown). 
Tissue sections were stained for t-PA, u-PA, u-PAR, PAl-I and PAI-2. Typical examples 
of immunohistochemical staining are shown in Figure I. The total number of lesions which 
stained for the different components are summarized in Table 1. In Figure 2, the percen-
tage of stained melanocytic cells per cell type of uveal melanoma is displayed. 
t-PA 
In all lesions abundant t-PA immunoreactivity was found in the wall of blood vessels 
(Figure la). The correlation between t-PA expression and cell type is shown in Figure 2: 
42 out of 45 tumors contained t-PA, however a moderate to abundant staining (>5 % 
tumor cells, n=16) was seen predominantly for non'spindle cell type tumors (14116). 
Interestingly, in 4 tumors t-PA staining was strikingly in nests of pleiomorphic epithelioid 
cells. These cells were located perivascular at both invasive fronts, towards the sclera 
(Figure Ib) and towards Bruch's membrane (Figure Ic). There was no relationship between 
percentage oft-PA positivity and TRD. All metastases contained t-PA. 
Figllre 1: Immullohistochemical staining of compol/eIIls of the plasminogen aCI;\'ator system illfre.~" /mlllalllH'eal 
melallOJlUllesiollS, 1Ypical slainillg examples ill primary lesiolls (a-c, e-g) ami a metastasis (d) are sholln. a: /-PA 
protein ill blood ~'essels. t-PA presel/t ill (1Il1/or cells at the scleral (Sc) ;1U'aSive front (b, arrowhead shows a 
"en'e) and ;11 tflmor cells adjacmt 10 Ihe retillal pigmelll epithelium where Bruch's membralle (Br) is ruptured 
(rflpture 1I0t seell)(c). d: It-PA is present ill tflmor celL~ ill tltis metastatic lesioll. e: /I-PAR is located at the 
itwosj\'e frolll tOll'ards the sclera ill litis lesioll. f: Iletll'OIk like PAl·] distriblltion ill the extracellular mafriT: 
surroundillg tllmor cells. PAI-2 was joulld focally ill the stroma (g) ami ill fill/lOr cells (IIOt shOIl'II). Cell types: 
spbuile cell Illmors (a) amilloll-spindle cellllllllOl"S (b-c, e-g). 
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Table 1 Imm/lllohistochemical staillillg of the compOllelllS of the plasmillogell actil'atiol/ 
system iI/ primary /lvealmelallomas alld iI/metastases of /lvealmelalloma. 
Eriruary uveal melanoma (0-45) 
Spindle (n=I4) 
t-PA 
u-PA 
u-PAR 
PAI-I 
PAI-2 
Non-spindle (n=31) 
t-PA 
u-PA 
u-PAR 
PAI-I 
PAI-2 
Metasfases....oLtlVeai..Jnelanoma"(n = 5) 
t-PA 
u-PA 
u-PAR 
PAI-I 
PAI-2 
t' s e total 
13 
0 
3 
2 
0 
29 
5 
12 
5 
4 
5 
2 
3 
o 
3 
0 
2 
0 
16 
2 
5 
3 
3 
4 
o 
3 
0 
0 
I 
0 
5 
0 
0 
2 
3 
I 
o 
I 
o 
13 
0 
3 
3 
0 
29 
5 
14 
3 
5 
5 
5 
2 
4 
If = stai/Jing ojllll1107 cells,. s = stromal cells; e = extracellular matrix stailled ill these lesions. 
/I-PA alld /I-PAR 
While no u-PA expression could be detected in any spindle cell type tumors tested, focal 
u-PA staining «5%) of tumor cells as well as staining of fibroblast-like cells was detected 
in 5 non-spindle cell tumors. In 2 cases u-PA expression correlated with TRD, one patient 
is known to have metastases, and for 2 patients follow-up was short (32 and 18 months). 
All 5 metastases expressed u-PA protein (Figure Id). 
Focal u-PAR immunoreactivity «5%) was seen in 15 tumors; 11 out of 15 were non-
spindle cell tumors. Both tumor cells (Figure Ie) and stromal cells showed a cytoplasmic 
staining aspect. Two metastases contained u-PAR. 
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PAI-I alld PAI-2 
PAI-I protein was observed in only 6 primary tumors (3 were of the spindle cell type), but 
in the majority of metastasis lesions (4 out of 5). The localization was in tumor cells and in 
the extracellular matrix (Figure If). 
PAI-2 protein was observed in a 5 out of 45 tumors and was found only in lesions of the 
non-spindle cell type. PAI-2 was expressed both by tumor cells and fibroblast-like cells 
(Figure 19). One metastasis contained PAI-2. 
In 2 out of 5 u-PA positive tumors, u-PAR and PAl were found in the same lesion, both 
patients died from metastatic disease. One of these two patients showed expression of all 
five components. A trend towards higher expression (higher percentage of immunoreactive 
cells) and a higher percentage of positive lesions in non-spindle compared to spindle cell 
lesions for t-PA, u-PA, u-PAR and PAI-2 can be deduced from figure 2. 
t-PA u-PA 
PAI-1 PAI-2 
01-5 % Iili:iIS-25 % _ 25-100 %, tumor cells 
C-:::] total percentage or lesions with Immunoreactivity 
u-PAR 
o~1 
'w 
r.on"'pl'l<l'& 
Figure 2. Percentage of ilJllIIl/lIohislocliemically stained fill/lOY cells alld percentage immunoreactive lesions 
i1lcluding stainillg of extracellular malyi ... alld stroma cells (e alld s ill Table 1), expressed as percelltage of the 
totall/limber of lesions. Four/eell IUlllors had purely spindle cell type (spil/d/e) morphology ami 3111111/0T5 (either 
of mixed or;g;1I or pltrely epithelioid) colltailled epithelioid cells (1IOn-sphulle). III lIoll-spindle cell melanomas, a 
higher percellfage of positive lesio/ls ami higher percentages of positiw cells is observed for t·PA, u·PA, Il·PAR 
alld PAI·2. Metastases are excluded from this diagram due the loll' II/f//wers il/cluded ill this slIldy. See also 
Table I. 
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III Situ Zymograpl/y 
In situ zymography was performed on sections of all lesions studied. In all cases, t-PA 
activity was found, often in a dotty pattern (Figure 3,first row). By comparing the lysis 
pattern with the hematoxylin and eosin stained sections, we could assign t-PA activity to 
blood vessels. Lysis in tumors with t-PA immunoreactivity in the highest category (25-100 
%) occurred faster and more general throughout the section (compare Figure 3, first and 
second row). Also in a few metastases we could detect t-PA activity in an area with mainly 
tumor cells (Figure 3, third row). Except for the positive control BLM and MV3 
xenografts (Figure 3, fourth row), no u-PA activity could be detected in all lesions studied. 
neg. 
control 
t-PA+ 
u-PA 
t-PA u-PA 
Figure 3: III situ zyll/ograp/ty oll/resh In'eaimelolJoc),lic les;oJlS, Plasminogell actil'lllioll was f·PA mediated ill all 
cases sludied alld located ill blood )'essels alUl ill tllmor cells. EmmpJes are shOWIJ of three cases. Olle 1I01l· 
spindle IIveal melanoma had I·PA immulloreactivity ill blood vessels hilt 110/ ill III/11or cells (first row). Olle 11011-
spindle Iweal melalloma where 5·25 % of the fllmor cells stailled for I-PA ill illllllllllohis/ochemislry {secOJuf rOI\~, 
1I01e that lysis is more abundant at the sclera sile (arrow). Also a melastasis oj m'eal melanoma (t!tird row) 
showed more generalized I-PA mediated lysis. A It-PA posiliw MV3 xenograft, where f·PA mediated Iysls liad 1/0/ 
yet occurred, is illcluded (jourlh rOI\~. Columns: lIeg. cOlltrol: casein layer W;/hOIlI plasmillogen; ,u,P4 + I·PA: 
casein layer witli addifioll oj plasminogen; I-PA: casein layer + plasminogen + poiycloll£ll allfibody against II-
PA; u·PA: caseill fayer + plasminogen + poiycloll£ll antibody agaiml f·PA. Incubalioll times at 37°C: 5 hours 
ill allln'eal melanoma cases (/oP three rows) and olle hOllr (fourth rOll:). 
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Discussion 
We recently studied the involvement of plasminogen activation in melanoma tumor 
progression both in a nude mouse system and in the in vivo situation on sections of fresh 
human cutaneous melanocytic lesions. u-PA, PAI-l and PAI-2 expression in human 
melanoma cell lines correlated with a high metastatic capacity in nude mice. All cell lines 
contained t-PA and u-PAR (16). In human cutaneous melanocytic lesions, u-PA, PAI-l and 
PAI-2 but also t-PA and u-PAR were found in the most malignant lesions only (advanced 
primary melanomas and melanoma metastases) (22). Here, we extended our study on the 
involvement of the plasminogen activation system in melanocytic lesions to uveal 
melanoma. Once the diagnosis of metastatic disease in uveal melanoma is made, (usually 
by fine needle aspiration), the following median survival is only 2-4 months (33,34). 
Therefore metastatic tissue is hard to access and only five metastases were studied. Little is 
known about the presence of proteases in uveal melanoma lesions. The involvement of 
proteases in metastatic spread of uveal melanoma has recently been suggested by Cottam et 
al. (35), who detected the 72 and 92 kD type IV collagenase in cu1tu~e medium of 15 
primary cultures of uveal melanomas. Furthermore, (-PA activity in supernatants of 
primary cultures of uveal melanoma seemed to correlate with scleral invasion in the tumor 
lesion, whereas no u-PA activity could be detected (36). Interestingly, the choroid itself ex-
presses t-PA (37) and u-PA (38). 
In our study, t-PA protein was expressed by tumor cells in the vast majority of the lesions. 
Expression of t-PA in uveal melanoma therefore does not differ from previous reports on 
melanoma as a source for (-PA: abundant (-PA was found in melanoma cell lines 
(16,26,27) and in cutaneous melanocytic lesions (26). t-PA was expressed in a larger 
percentage of the tumor cells in non-spindle cell tumors. Immunoreactive cells ofien had a 
perivascular localization. Also, the localization of t-PA positive cells at both the scleral and 
Bruch's membrane invasion front was remarkable. This observation is in agreement with 
Cottam et a1. (36), who found that elevated t-PA activity in primary cultures of uveal 
melanoma correlated with scleral invasion. t-PA positivity was noted in varying percentage 
(0% up to 25-100% categories) ill patients which already died from TRD as well as in 
patients which were still alive. No relationship between extent of t-PA positivity and TRD 
could be established. 
u-PA expression was found focally in only 5 primary uveal melanomas. Interestingly, all 
these lesions were of the non-spindle type. In 2 cases u-PA expression correlated with 
113 
Plasmillogell Activatioll System ill V.'eal Melalloma 
TRD J one patient is known to have metastases and for two patients, follow-up was 
relatively short. Also, all metastases contained u-PA positive cells. Therefore, a clear 
association with progression of disease exists, as could be found for some other types of 
tumors (17, 19-21), including cutaneous melanoma (22). Furthermore, u-PA positivity 
might be an additional prognostic marker for uveal melanoma. Nevertheless, six cases with 
TRD did not display u-PA positivity. Therefore, though the relation between u-PA 
positivity and progression of disease could be demonstrated in this study, a more extensive 
study has to be performed to determine whether u-PA is a valuable prognostic marker for 
uveal melanoma. 
With in situ zymography, we were only able to detect t-PA (both blood vessel and tumor 
cell associated) and no u-PA activity, which is in agreement with findings in primary 
cultures of uveal melanoma (36). Apparently, the u-PA detected by immunohistochemistry 
is either of the inactive pro-form or inactivated by PAl. This view is supported by the fact 
that the staining was only cytoplasmic, where u-PA is normally in the inactive form. Also, 
the in situ zymography with region sensitivity rather than cellular sensitivity, might be too 
insensitive to detect less than 5 % scattered u-PA positive cells. 
The expression of u-PAR in by far more lesions than u-PA is remarkable, though it is in 
agreement with our earlier findings in human melanoma cell lines (16), where all cell lines, 
including the non-metastatic ones, expressed u-PAR. u-PAR was found cytoplasmic, 
indicating that at least a portion of u-PAR was not available for binding to pro-u-PA (10). 
Receptor bound pro-u-PA is more efficiently converted to active u-PA (6,12). 
For t-PA, u-PA, u-PAR and PAI-2, a higher expression (higher percentage of staining as 
well as a higher number of lesions involved) was found in the non-spindle cell uveal 
melanomas (Figure 2) as compared to the spindle cell melanomas which have a better 
prognosis. These observations and the fact that these components were also frequently 
detected in metastases, suggests a tendency with progression of disease in this study. 
Surprisingly, though 4 out of 5 metastases were positive, in primary tumors, this tendency 
could not be established for PAl-I, which is a prognostic marker for mammary carcinoma 
(18). 
By comparing the involvement of the PA system in uveal and cutaneous melanoma (22), 
we can summarize the following differences: I) Using the same polyclonal antibody, t-PA 
was found in almost all primary and metastatic lesions of uveal melanoma, whereas in 
cutaneous melanoma, only a few metastases contained t-PA positive tumor cells. 2) In 
cutaneous melanoma, lesions expressing u-PA expressed also u-PA's regulators u-PAR and 
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PAL For uveal melanoma, this co-expression was not as profound (Figure 2). 3) Uveal 
melanomas express u-PA, PAl-I and PAI-2 in approximately 10 % of the lesions, whereas 
in cutaneous melanoma approximately 60 % of the thicker primary lesions were positive. 
In addition, less tumor cells stained in uveal immunoreactive lesions (all u-PA, PAl-I and 
PAI-2 positive lesions were scored in the 1-5 % category). Similar to cutaneous melanoma, 
u-PA is associated with progression of disease in uveal melanoma. In uveal melanoma, 
other proteolytic systems could be of more importance in metastatic spread, compared to 
cutaneous melanoma. 
From our study, we conclude that in uveal melanoma, u-PA expression may be associated 
with metastatic disease and accordingly with poor prognosis. In our opinion, it would be 
worthwhile to extent research on the presence of u-PA in uveal melanoma to a large group 
of tumors with known follow-up. In this way, it would be established whether u-PA 
positivity is of additional prognostic value in uveal melanoma. 
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Summary 
Tumor cell adhesion, detachment and aggregation play an important part in tumor invasion 
and metastasis. Cell adhesion molecules are frequently expressed by tumor cells. It has 
been demonstrated that cell adhesion molecules of the immunoglobulin superfamily are 
associated with the development of metastatic behavior in cutaneous melanomas. In order 
to investigate the role of neural cell adhesion molecule in the development of metastatic 
behavior, we studied immunohistochemically the expression of NCAM and HNK-I on a 
series of primary uveal melanomas and their metastases. We studied 31 primary tumors 
(among these, 10 were rapidly metastasizing and 16 slowly metastasizing) from 31 patients 
and 29 metastases from 20 patients. From 13 patients the primary as well as the metastatic 
tumor were available. HNK-I was expressed in a lower percentage of all tumors than 
NCAM. Although NCAM and HNK-l were expressed in relatively benign, slowly 
metastasizing primary tumors, we observed an increase of expression in aggressive, rapidly 
metastasizing tumors, as wetl as in metastases. There was no similarity between expression 
of NCAM or HNK-l in the primary tumors and their corresponding metastases. This 
implies that cell adhesion molecule expression is not a constitutive characteristic of tumor 
cells. HNK-I was negative in 95% of the liver metastases, and negative in 42% of other 
metastatic sites. The HNK-I antigen may therefore playa role in the organ specific 
metastatic behavior of uveal melanomas. 
Introduction 
Adhesive properties of malignant cells must change repeatedly in order to allow them to 
detach from their primary location, attach to the extracellular matrix, enter a blood vessel 
and eventually lodge at a metastatic site. I Cell-cell interactions mediated by cell adhesion 
molecules (CAM) play an important role in these processes.' The neural cell adhesion 
molecule (NCAM) and the intercellular adhesion molecule (ICAM) belong to the 
immunoglobulin (Ig) superfamily.2.3 In a variety of human malignancies, tumor progression 
has been observed to be associated with changes in NCAM expression.'" For cutaneous 
melanoma it has been demonstrated that the development of metastatic potential is 
associated with 'de novo' expression of ICAM-l'" and MUCI8,' an antigen which shows 
sequence similarity to NCAM.'·JO In contrast, Denton et a1.(1992) found expression of 
MUCI8 on a full range of benign and malignant melanocytic lesions. II In uveal 
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melanomas, melanoma-associated CAM-I appeared to be negative l ' or poorly expressed13.I ' 
compared to cutaneous melanomas. ICAM-I could not be detected in one study, I. but using 
a different anti-ICAM-I monoclonal antibody (MAb) most of the uveal melanomas 
stained,13.1S with a preferential reactivity of the mixed and epithelioid cell typeY Uveal 
melanomas metastasize relatively latel6,17 and in contrast to cutaneous melanomas primarily 
hematogenously, preferentially to the liver. Once hepatic metastases are clinically present, 
the median survival is extremely poor: only 2-11 months. 18 A role for NCAM in the 
development of malignant potential of uveal melanomas has so far not been reported. 
The purpose of the present stndy was to investigate if NCAM expression is correlated with 
the development of metastatic potential in uveal melanoma. We stndied primary tumors 
with known clinical outcome (including rapidly metastasizing and clinically non- or slowly 
metastasizing tumors) and all available metastases. We report here on NCAM which was 
stained by a polyclonal antibody, that recognizes all three major NCAM isoforms, and 
HNK-I, a carbohydrate epitope present on some NCAM species which is stained by the 
Leu-7 MAb. 
Mated.ls alld Methods 
Paliel1l Seleclion 
From the files of patients with uveal melanoma related death, we were able to collect 
metastatic tissue from 19 patients (\ 0 liver biopsies, I skin biopsy, I autopsy, 7 fine needle 
aspirations). From 13 of these patients the paraffin blocks from the primary ciliary body or 
choroidal melanoma were available; their follow-up varied between 6 months and 147 
months (mean follow-up: 47.4 months). From 5 of these patients paraffin blocks from the 
primary as well as the metastatic tumor were available. Uveal melanomas create a peak 
incidence of mortality during the second and third years following enucleation, irrespective 
of the largest tumor diameter. 19 Tumor related death within 3 years was therefore 
considered to be due to rapidly metastasizing melanoma (fable I). Furthermore, we 
selected 9 patients with a follow-up of at least 10 years after enucleation without clinical 
evidence of metastatic disease, of whom paraffin blocks of the primary tumor were 
available. These melanomas were considered to be of low metastatic potential (fable 2). 
The total mean follow-up of this group was 175.8 months. FrOm nine patients, the paraffin 
blocks from the primary uveal melanomas and eight corresponding metastases (4 autopsies, 
4 biopsies) were obtained from the Eye Pathology Institute in Copenhagen: the follow-up 
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varied between 2 and 32 years (mean follow-up: 14 years). Three were rapidly 
metastasizing melanomas(Table 1) and six were of low metastatic potential (Table 2). All 
these patients died of tumor related death. 
Therefore, the total material consisted of 31 primary tumors. Among these, 10 were 
rapidly metastasizing (Table 1) and 16 slowly metastasizing (Table 2); the remaining five 
deceased due to uveal melanoma related death between three and 10 years. We investigated 
29 metastases (Table 3) from 20 patients. Of 13 patients tissue from the corresponding 
primary and metastatic tumors were available. 
Histology 
Sections were cut at 5 to 6 I'm and stained with hematoxylin-eosin. Of the primary tumor 
the predominant cell type (spindle, mixed or epithelioid) and largest tumor diameter (dO 
mm, 10-15 mm, > 15 mm) were recorded. 
IlIIlIIUIIOhistochelllistlY 
Paraffin sections, 6-7 I'm thick were cut and mounted on aminopropyltriethoxysilane 
(APES, Sigma, SI. Louis, USA) coated glass slides and dried overnight at 37°C. After 
deparaffinizing and rehydrating, endogenous peroxidase activity was blocked by incubation 
for 20 minutes in methanol containing 3 % hydrogen peroxide. The following specific 
antibodies were used: 
1) NCAM: A polyclonal rabbit antibody specific for NCAM was used." This antibody 
recognizes all three major NCAM isoforms irrespective of the presence or absence of 
polysialylation. 21 After rinsing the slides in water, antigen retrieval was performed by 
microwave irradiation (Bio-Rad 3rC, 750 Watt, 2x 5 minutes in 0.1 % pronase). The 
slides were incubated with phosphate-buffered saline (PBS) at 4°C for 10 minutes and 
subsequently at room temperature (RT) for 5 minutes. The NCAM antibody was incubated 
for 30 minutes in a dilution of 1: 100 at RT. Visualization of antibody binding was 
performed as described below. 
2) The monoclonal antibody HNK-I (Leu-7), raised against a T cell lymphoma (Becton 
Dickinson) was used in a dilution of 1: 10 and incubated for 30 minutes at RT. The slides 
were incubated for 30 minutes at RT with biotinylated goat-anti/mouse/rabbitlrat/guinea-
pig immunoglobulin (Ig) (Biogenex) in a dilution of 1:50, in PBS with 5% BSA. After 
washing in PBS/Tween 0.05%, the slides were incubated with the streptavidin-biotin-
peroxidase complex (Biogenex) in a dilution of I :50. The peroxidase was visualized using a 
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hydrogen peroxide in N-N-dimethylformamide with 3-amino-9 ethylcarbazole 
dimethylformamide as chromogen substrate. The red stain allowed easy detection of 
immunoreactivity in pigmented lesions. The sections were counterstained with Mayer's 
hematoxylin and mounted in glycerin gelatin. 
As a negative control, specimens were stained following the same incubation protocol 
without use of the primary antibodies. A human neuroblastoma served as a positive control 
for NCAM. For HNK-I, nerve tissue present in the tissue section served as an internal 
positive control. 
NCAM and HNK-I immunoreactivity were scored semi-quantitatively as percentage of 
positive cells: score 0: 0%, score I: 0 - 5%, score 2: 5 - 50%, score 3: 50 - 100%. The 
immunohistochemical staining was scored without knowledge of the clinical data and was 
repeated after 2 months. Major (> 2 classes) discrepancies did not occur. 
Results 
PrimalY Tumors 
Thirteen tumors were of the spindle cell type, 14 of the mixed cell type and 4 of the 
epithelioid cell type. Four tumors were small « 10 mm), 21 were intermediate size (10-15 
mm), and six were large (> 15 mm). 
NCAM positive tumors showed strong cytoplasmic staining; in three cytoplasmic (Figure 
la) and membrane bound staining was noted (Figure Ib). The results for NCAM 
expression in the different cell types are illustrated in Figure 2. Of the spindle cell tumors 
31 % were strongly positive (score 2 + 3) as were 71 % of the mixed cell tumors, and all 
epithelioid cell tumors. Of the small tumors, 50% were strongly positive for NCAM (score 
2 + 3) as were 53 % of the intermediate size, and all large tumors. Of the rapidly 
metastasizing tumors 70% (Table I) and of the slowly metastasizing tumors (Table 2), 
37.5% were score 2+3. 
In the HNK-I positive tumors, strong cytoplasmic staining was noted (Figure 3). 
Of the spindle cell tumors 15% were positive (score 3); of the mixed cell tumors 22% 
(score 2+3) and of the epithelioid type 25% (score 2). The small tumors were all negative 
for HNK-I; 14% of the intermediate size and 50% of the large tumors were score 2+3. Of 
the rapidly metastasizing tumors 30% were positive for HNK-I (score 2+3, Table I), 
whereas 12.5% of the slowly metastasizing tumors were positive (score 3, Table 2). 
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FIGURE la alU/lb. Field a/uveal melalloma 
of tfle epithelioid cell f)'IJe immllllOsfailled for 
NCAM. Cytoplasmic stai/ling is represented ill 
Figure la (origilwll1Ulgllijicafioll x 361). 
membrane-boulld stainillg ill Figure Jh 
(origbwl magnificatioll x 880). (llemato:tylilJ 
COllllferslaill with strepta~'idill·bioti/J·peroxidase 
complex i/lIIl1lf1lOperm"idase with 3-amillo-9 
eilly/carbazole dimethyiformnmide substrate). 
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mewllo11/a immlfJlOstailledjor HNK-l. 
(Hematoxyli/l coullferstail) willi strep/(widill-
biotill-peroxidase complex imml/J/Operoxidase 
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dimethyljonll(lmide substrate; original 
magnificatioll x 361}, 
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Table 1 Immullohistochemical data of melanomas melastasizing within 3 years 
Pat. Cell Follow-up* Prim. Corr. Prim. Corr. 
no. type (months) mel. met. mel. met. 
NCAM NCAM HNKJ HNKol 
S 15 n.a. 0 n.a, 
2 E 32 2 n.a. 0 n.a. 
3 M 27 2 0 0 0 
4 M 15 2 l1.a, 2 l1.a. 
5 E 19 2 n.a. 0 l1.a. 
6 M 15 0 n.a, 0 l1.a. 
7 E 6 2 l1.a. 2 n.a. 
8 M 36 0 3 3 0 
9 M 30 3 n.a. 0 !l.a, 
iO M 24 2 n.a. 0 2 
*: All patiellls died (if flllllOr-rt'lated deafh, Prim. md.: primlll)' /l1'ea/melalloma. Corr. 1IIe(: Correspolldillg 
melosras;s. E: epithelioid cell type, AI: miw'd cell type, S: spilldle cell type. lI.a.: para.bill block 110/ amitable. 
Score 0= lIegath'e; score 1= 0-5% tlfl/lor all .. positive: ,~c()re 2== 5-50% t/lmor cells positi\'e: score 
J= 50-100% t/ill/or celL~ positi\'t'. 
125 
Nellral Cell Adhesion MoleclIle Distriblltion 
Table 2 Immllnohistochemical data a/melanomas wilh a/allow-lip 0/ > 10 years 
Pat. Cell Follow-up Prim. Corr. Prim. Corr. 
no. type (months) mel. met. mel. met. 
NCAM NCAM HNK"l lINKd 
M 224 2 • 0 • 
2 S 223 0 • 0 • 
3 S 228 0 • 0 • 
4 S 209 0 * 0 * 
5 S 165 0 * 0 * 
6 S 182 0 • 0 • 
7 S 181 2 * 0 * 
8 M 125 0 • 0 • 
9 S 151 • 0 • 
IO S 147 2 n.a. 3 n.a. 
II M 130 3 0 0 
12 S 192 3 2 3 2 
13 S 300 0 2 0 3 
14 S 192 3 2 0 0 
15 S 384 0 3 0 0 
16 M 216 2 3 0 0 
Prim. mel ... Primary uveal melanoma: corr. mer.: correspOIulillg metastasis. *: patiems ali\'e alld free of 
metastatic disease after> 10 years: " tumor-related dea'" after> /0 years. S: spindle cell type, M; mixed cell 
type, E: epithelioid cell type. lI.a.: paraftlll block 1I0t al'ailab/e. 
score 0= llegat;\'e; score 1= 0-5% tU11/0r cells positive: score 2= 5-50% tllmor cells posi/h'e; score 3= 50-
100% hIll/or cells posilh'e 
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Table 3 Stailling pattern in the metastases 
NCAM HNK-l 
neg. #1 #2 #3 ratio neg. #1 #2 #3 ratio 
Liver 
pos. pos. 
3 6 5 12115 14 1115 
Lung 
6 2 8/9 5 3 4/9 
Skin· 
2 2/4 2 3/4 
Abdomen· 
0/1 1 111 
Total* 
5 14 7 20 6 2 
#: score. Score J = 0-5% positi\'e tumur cells, score 2 = 5·50% positive fUll/or cells, score 3 = 50-100% 
posith'e ///Il/or cells. *: olle metastasis from tlte skill {lwl olle mefastasis from Ihe abdomell were /lIIclassifiahle jor 
NCAM. Ratio pos.: ralio posit;w les;olls/(o/allesiollS metastatic site. 
Metastases 
The staining pattern of all metastases for NCAM is illustrated in Figure 2; the staining 
pattern in the different organs is specified in Table 3. For NCAM, 72% of the metastases 
stained (score 2+3). For HNK-I, 27% of the metastases stained (score 2+3). Of the 15 
liver metastases, only one was positive for HNK-I (Table 3), whereas 42% of the other 
metastatic sites were negative. In 5 autopsies, different metastases from the same subject 
had a varying score (from negative to score 3) both for NCAM and 
HNK-l. 
Corresponding Primary and Metastatic Tumors 
Of 13 tumors pairs (partly reflected in Table I and 2), 8 primary tumors and their 
metastases showed positive staining; in 5 major (negative versus positive) discrepancies 
between the primary tumor and the metastases were noted. 
Relationship Between HNK-J and NCAM 
With one exception, all HNK-I positive primary and metastatic tumors were also positive 
for NCAM. However, 71 % of the primary tumors were NCAM positive, whereas only 
20% were HNK-I positive. Similarly, of the metastases 72% were NCAM positive and 
27% were HNK-I positive. 
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Discussion 
The percentage of NCAM positive tumors in our study was higher than has been reported 
for cutaneous melanomas. '.11.22 This might be explained in terms of methodological 
differences: we used a different (polyclonal) antibody on formalin-fixed, paraffin 
embedded tissue and also applied an antigen retrieval method. NCAM immunostaining was 
mostly cytoplasmic and less frequently both cytoplasmic and membrane-bound, which is in 
keeping with previous investigations. 5,22 
HNK-l was expressed in a lower percentage of the tumors than NCAM, but was rather 
consistently expressed in NCAM positive tumors, primary as well as metastatic. NCAM 
expression was noted in a high percentage of liver metastases as well as in lung and pleural 
metastases. Interestingly, 95% of the liver metastases were negative for HNK-l, in contrast 
to other metastatic sites. These findings might suggest a possible role for the HNK-l 
antigen in the organ-specific pattern of uveal melanoma metastasis. 
We found an increase in NCAM and HNK-I staining in lesions with epithelioid cells 
(mixed and epithelioid cell type). This is in concordance with the findings for cellular 
adhesion molecule ICAM-l in primary uveal melanoma."'" The presence of epithelioid 
cells is one of the factors associated with progression of uveal melanomas (development of 
metastatic potential)." Furthermore, we found an increase in NCAM and HNK-l staining 
in large tumors, in rapidly metastasizing tUl11ors, and in metastases. NCAM and HNK-l 
expression in the primary tumors did not correspond with that in the paired metastases, 
indicating that NCAM and HNK-l expression are not a constitutive characteristic of the 
tumor cells. Immunohistochemical studies on the relationship of NCAM expression with 
tumor cell typing are rare.'·6.1I.2I.22.24.26 The antibody to NCAM we used in our study has 
been investigated on cell lines of human small cell lung cancer, 27 glioma cells18 and murine 
melanoma cells.29 In these cell lines it has been found that metastasizing cells express less 
NCAM than non-metastasizing cells,28.29 which contrasts with OUf findings on formalin-
fixed, paraffin embedded tissue. However, we found that NCAM and HNK-I expression in 
3 uveal melanoma cell lines did not correspond with that in the tissue from which the cell 
lines were derived (data not shown). This indicates that expression of cell adhesion 
molecules may be modulated by the tumor cell microenvironment. Alternatively, tissue 
processing might interfere with NCAM immunoreactivity. 
That NCAM is expressed in epithelioid cells seems surprising because epithelioid cells are 
morphologically nOll-cohesive. It is not clear how adhesion molecules on the surface of 
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cancer cells influence metastasis. Adhesion molecules may delay the escape of tumor cells 
from the primary site due to an increased adhesion to other cells and to intercellular matrix 
proteins. However, an altered pattern of CAM expression or expression of aberrant CAM 
might disrupt normal adhesion and attachment of these cells to a blood vessel or a 
metastatic site.4 
NCAM exhibits special carbohydrate characteristics: glycosylation of NCAM seems to be 
regulated during development and to influence the adhesive function of the molecule. 30 It 
has been suggested that pOlysialylated NCAM present in early (embryonic and fetal) stages 
of development is involved in cellular migration, whereas the expression of unsialylated 
NCAM in tissues may be important for local differentiation and organization." Polysialyla-
tion of the NCAM molecule decreases its adhesion properties and may therefore playa role 
in connection with tumor invasion and metastasis. Immunohistochemical investigation gives 
information about the subcellular localization of NCAM, but does not enable distinction 
between the different isoforms, neither does it provide information about NCAM 
pOlysialylation. 
In summary our results show that expression of NCAM and to a lesser extent of HNK-l is 
associated with the development of malignant potential of uveal melanoma. The prognostic 
value of NCAM and HNK-I expression in uveal melanoma remains to be established. 
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Considerations 
Approximately 40% of the patients with ciliary body and choroidal melanoma who undergo 
enucleation die within 10 years after diagnosis of metastasis.' Nevertheless, clinically 
evident metastatic disease at the time of initial presentation of the primary tumor is 
uncommon, metastases being detected in only 1 to 2 % of patients; furthermore, death due 
to local recurrence is extremely rare. These findings imply that subclinical metastatic 
disease is more common than previously assumed. There is currently no effective therapy 
once clinically detectable metastases have developed. Metastatic dissemination in uveal 
melanoma is almost exclusively hematogenous, preferentially to the liver. The development 
of metastatic disease subsequent to surgical removal of the primary tumor implies that 
undetectable micrometastases must be present at initial presentation already. Identification 
of patient subgroups with increased risk for the development of metastases might be 
important when effective adjuvant treatment for micro metastases would become available. 
Against this background we made an effort to identify prognostic factors which would help 
to recognize patients at high risk of developing metastatic disease .. 
Prognostic Parameters 
Histologic cell typ~ and largest tumor diameter (LTD) have traditionally been regarded as 
the leading predictors of survival. Ideally, histopathological prognostic parameters should 
be simple to assess, reproducible, and amenable to analysis in conventionally processed 
tissue specimens. Morphological cell typing of uveal melanomas is however, SUbjective to 
variations in interpretation. Cell typing according to the modified Callender classification' 
appeared no longer as an independent prognostic parameter after multivariate analysis in 
several studies. 3.6 Therefore, Callenderls classification has been further modified into a 
two·category system: tumors with and tumors without epithelioid cells. 3 The prognostic 
value of this system needs to be investigated further. More objective classification 
parameters have emerged from cytomorphological and DNA flow-cytometrical studies. We 
have demonstrated that DNA-ploidy and cell type are strongly correlated. Furthermore, we 
found that DNA-ploidy and LTD appeared to be the most significant parameters in 
predicting clinical outcome. In most studies LTD appears as one of the most significant and 
reproducible parameters in predicting survival. Although, the sensitivity of LTD as 
prognostic parameter has been reported to be 76%, the specificity was only 44% which 
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allows for a 56% chance of a false prediction of outcome.' 
It has been calculated that the median survival time for patients with an LTD of lO mm is 
substantially longer than the median survival time of patients with LTD of 20 mm and the 
linear doubling time from the primary tumor J estimated on clinical data, suggest. 1,7 This 
implies that as tumors grow, they progressively disseminate progressively more rapidly 
proliferating cells, which further attenuates the inverse relationship between LTD to 
survival time. Tumor height or extrascleral growth have not been reported as independent 
prognostic parameters in recent studies on multivariate analysis of prognostic factors. The 
TNM classification of uveal melanomas might provide a model of progression in 
combining LTD, tumor height and scleral invasion in the T category. However, in our 
study of DNA-ploidy, T classification did not appear to be of prognostic significance. 
In a clinical study, it has recently been demonstrated that delayed treatment of selected 
small and dormant appearing choroidal melanomas does not substantially increase the 
probability of melanoma-specific mortality.8 Nevertheless, even small or pure spindle cell 
melanomas may give rise to metastases: although for tumors < 7 mm death to metastatic 
disease is only sporadically reported,' the 5-year mortality rates in patients' with melanomas 
< lO mm is reported to be 16%.10 Therefore, prolonged clinical observation of melanomas 
from 7 mm to lO mm diameter is doubtful. 
Fine needle aspiration of intra-ocular tumors has proven to be a safe and useful technique" 
and appears to be reliable in distinguishing between melanomas and metastatic lesions and 
other primary tumors. However, the cytological differentiation between nevi and small 
melanomas remains a problem. Techniques such as DNA-ploidy measurements and 
determination of proliferative activity can be applied to fine needle aspirates in order to 
select from patients with clinically small tumors and therefore with an overall low risk for 
metastatic disease, those with a high risk and a need for further treatment. Furthermore, 
these techniques can be applied to fine needle aspirates from iris and/or ciliary body 
tumors, which clinically give rise to problems in differentiating between nevi and 
melanomas. 
The presence of closed vascular loops has been proclaimed the parameter most significantly 
associated with tumor related death of all variables tested.'·I2·" However, the 
reproducibility of the differentiation between the various vascular patterns and the 
prognostic value of this parameter remains to be proven by independent additional studies. 
It is apparent that important trends have emerged from retrospective prognostic studies. In 
a prospective study on a large series of uveal melanomas the prognostic value of 
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histopathological covariates like cell type, LTD, the vasculature pattern, the Mib-l index, 
c-myc oncoprotein and possibly DNA-ploidy and nucleolar measurements like standard 
deviation of the nucleolar area" needs to be further investigated. The Mib-l index and c-
myc oncoprotein can currently be routinely determineo by immunohistochemistry. Thus, a 
combination of prognostic parameters might be selected with high sensitivity and 
specificity. If effective systemic treatment for metastatic uveal melanoma would be 
available, such an approach might provide a way of selecting patients at high risk of 
developing metastatic disease for adjuvant therapy. 
Tumor Progression 
At present, we know very little about the events which initiate the development of uveal 
melanoma or about the factors which promote their metastatic dissemination. The 
acquisition of this knowledge will provide us with more accurate indices of survival and a 
better prospect for cure. 
Based on clinical and histopathological studies, it has been proposed that tumor progression 
in cutaneous melanoma is a process of distinct steps) leading from a 'promoted melanocyte' 
to a metastatic melanoma (Table 1), IS although for each tumor not every step necessarily 
needs to be taken. 
Table 1 Proposed Tumor Progressiol/ il/ Cutaneous Melal/oma. * 
Step Melanocytic lesion 
1) Common acquired and congenital nevus 
2) Dysplastic nevus 
3) Primary melanoma, radial growth phase 
4) Primary melanoma, vertical growth phase 
5) Metastatic melanoma . 
• After Mel/rat! el at. 
For uveal melanoma, a similar model might be considered. Thus, for the different steps the 
role of various factors that playa role in the acquisition of metastatic potential might be 
investigated, which could open new ways to interfere with this process. 
In uveal melanoma progression, the steps can be proposed by histological cell type (Table 
2) or by LTD (Table 3). However, precursor lesions of uveal melanoma (choroidal nevi or 
atypical melanocytic hyperplasia) are rarely available for histopathological studies. In this 
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respect it seems important to obtain choroidal nevi J either from autopsies or from 
incidentally detected nevi in enucleated blind and painful eyes. Furthermore, a pre-
invasive, intra-epithelial (retinal pigment epithelium) precursor lesion has not been 
demonstrated in uveal melanomas. The advantage of LTD as a model of progression is that 
the different steps are highly reproducible and highly significant in predicting clinical 
outcome. 
Table 2 Proposed TUlllor Progression in Uveal Melanollla. 
Step Melanocytic lesion by cell type 
1) Choroidal nevus 
2) Primary melanoma, spindle cell type 
3) Primary melanoma, mixed cell type 
4) Primary melanoma, epithelioid cell type 
5) Metastasis 
Table 3 Proposed TUlllor Progression in Uveal Meiallollla. 
Step Largest tumor diameter 
1) ~ 7 mm 
2) 7 - 10 mOl 
3) > 10 mm - 15 mm 
4) > 15 mOl 
5) Metastasis 
A vertical growth phase is not recognized in uveal melanoma. However, at a certain point 
uveal melanomas invade the sclera or break through Bruch's membrane, grow into the 
retina and through the internal limiting membrane into the vitreous. We have investigated 
the role of cell-matrix interaction and found that the plasminogen activator system and 
neural cell adhesion molecule distribution play a role in the progression of uveal 
melanomas as defined by cell type. The prognostic value of these parameters and a possible 
role of other superfamilies of adhesion molecules in tumor progression remains to be 
established. Furthermore, we found that the Mib-l defined proliferative index and the 
regulating oncoprotein c-myc are independent prognostic parameters. The Mib-l index 
correlated with the presence of epithelioid cells, but a relationship between these 
parameters and LTD could not be established. Oncogene activation (i.e. N-ras mutations) 
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could not be demonstrated primary uveal melanomas. 
It seems likely that vascular invasion is a major step in the progression of uveal melanoma. 
Tumor classification of uveal melanocytic lesions, based on the microcirculation 
architecture by light and electron microscopy has been proposed: nevi had a characteristic 
vascular architecture and melanomas that have the same vascular profile had a very high 
probability to cause an intermediate biological behavior. Melanomas with closed vascular 
networks had a very high probability to cause death due to metastatic disease." However, 
nevi are rarely available for histological examination. Therefore, the vascular pattern of 
uveal nevi is of little practical value as point of reference. 
A furlher goal of investigation may be the reproducibility of the prognostic value of the 
vascular pattern and the development of the tumor vasculature, in particular closed vascular 
patterns, by studying the interaction between uveal melanoma cells and the exlracellular 
matrix. In particular the role of growth factors and their receptors in the angiogenesis of 
uveal melanoma needs to be elucidated. 
III Vitro Models 
In this models of uveal melanoma a major advance in research has been the development of 
culture techniques that allow the establishment of cell lines. When cell lines can be 
established from uveal melanomas, defining the steps between benign melanocyles and 
metastatic uveal melanoma, several biological and molecular properties might be studied in 
detail. Although such model systems do not necessarily reflect the situation in vivo, they 
can be helpful in determining the role of carcinogenesis related events, like abnormalities in 
cancer genes, autocrine and paracrine growth-stimulation, inhibition of apoptosis, cell 
adhesion and cell migration related molecules and matrix proteases in melanoma 
progression. Furthermore, elucidation of the molecular basis of the recognition of 
malignant cells by the host immune system could lead to the establishment of useful targets 
for specific immunotherapy of uveal melanoma. 
Anilllal Models of HUlllan Uveal Melanollla 
In order to develop new techniques for the systemic treatment of uveal melanoma, 
knowledge about the growth and organ specific metastasis of these tumor cells is a 
prerequisite. Transplantation of human uveal mehinoma cell lines into animal eyes has been 
used to study tumor growth and metastasis. It was established that in nude mice the success 
rate of xenografting of primary uveal melanoma tissue is low, and spontaneous metastases 
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from xenografts are rare,17,18 In immunosuppressed rabbits successful heterotransplantation 
has been described. 19•20 Recently, we developed a chicken embryo model to study the 
growth of human uveal melanoma.2I Further investigation of reproducible animal models is 
warranted. 
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Summary 
The aim of this thesis was the identification of reliable progression parameters as 
prognostic markers in primary uveal melanoma, focussing on clinicopathological 
characteristics. 
General background information on epidemiology, histologic classification, tumor grading, 
the survival and therapy of uveal melanoma patients is given in Chapter 2. The difficulties 
in reproducing the subjective histologic classification encouraged research on more 
objective parameters. From our review on advances in research on prognostic parameters 
(Chapter 3) new parameters appeared in the field of cytomorphometry (standard deviation 
of the nucleolar area and mean of the ten largest nucleoli) and DNA analysis (ploidy 
studies). From recent clinicopathologic studies it appeared that the tumor vasculature 
(presence of closed vascular patterns) is one of the most significant factors in predicting 
metastatic potential of uveal melanomas. Reviewing the relevant literature on identification 
of characteristics in the uveal melanoma genotype and phenotype revealed considerable 
differences in the field of cytogenetics in cutaneous and uveal melanomas. Furthermore, 
the specific surface phenotype of melanoma-associated antigens revealed marked 
differences between these tumors. So far, limited research has been performed on cell-cell 
and cell-matrix interaction, again indicating differences in uveal and cutaneous melanomas. 
This led to the conclusion that some of these findings may relate to the difference in 
biological behavior between these tumors. 
Progression in tumors can be defined as irreversible acquisition of metastatic potential. The 
benign or precnrsor lesions of uveal melanoma progression are difficult to obtain. In 
Chapter 4 we describe a rare case of -paraneoplastic- bilateral melanocytic hyperplasia 
which led to bilateral uveal melanomas. Our research in the field of the genotype of uveal 
melanoma revealed no mutations in the N-ras gene (Chapter 5). These mutations have been 
demonstrated in cutaneous melanomas and were attributed to the effect of UV radiation. 
Ki-67 defined proliferative activity was performed by immunohistochemistry on a series of 
uveal melanomas (Chapter 6). We compared melanomas, which had received irradiation 
prior to enucleation with non-irradiated melanomas. Our findings revealed that uveal 
melanomas which had not been irradiated prior to enucleation, had a significant higher 
proliferation rate. An association with clinico-pathologic parameters could not be 
demonstrated. To address the striking variation of aneuploidy reported for uveal melanomas 
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we performed DNA flow cytometric analysis on a series of melanomas (Chapter 7). A 
strong correlation between DNA-ploidy and cell type, but not with other 
clinicopathological parameters was demonstrated. Furthermore, we found that pre-
enucleation irradiated melanomas were significantly more aneuploid than non-irradiated 
melanomas. DNA-ploidy and LTD were the most significant factors, in predicting clinical 
outcome. We studied retrospectively indices of proliferation, such as mitotic count and the 
Mib-I (Ki-67) index on a series of uveal melanomas and compared their prognostic 
significance with clinicopathologic parameters. Along the same line we investigated the 
expression of the regulating proteins c-myc and BC\-2 (Chapter 8). We found that LTD, 
cytoplasmic expression of the c-myc oncoprotein and the Mib-I index were useful as 
independent prognostic parameters. The strong inverse relationship between the 
oncoproteins c-myc and Bcl-2 indicate that c-myc and BcI-2 opposite in immortalizing 
uveal melanoma cells. Degradation of the extracellular matrix and other tissue barriers is a 
prerequisite in the acquirement of malignant potential. An important proteolytic system 
involved in tumor progression comprises the proteins of the plasminogen activator (PA) 
system. We investigated the expression and distribution of the various components of the 
PA system and the presence of PA enzyme activity (Chapter 9). Although we found that 
urokinase-PA expression correlated with occurrence of metastasis, the prognostic value of 
u-PA remains to be established. At the invasive front (towards the sclera and Bruch's 
membrane) tissue-type PA was markedly present. The different components of the PA 
system were markedly less expressed compared to cutaneous melanomas. In Chapter 10 we 
investigated the role of neural cell adhesion molecules (NCAM) in the development of 
metastatic behavior in a series of primary and metastatic uveal melanomas. We found that 
NCAM and to a lesser extent HNK-I is associated with the development of malignant 
potential. The prognostic significance of these parameters remains to be established. There 
was no similarity between expression of NCAM or HNK-I in the primary tumors and their 
corresponding metastases, implying that cell adhesion molecule distribution is not a 
constitutive characteristic of tumor cells. HNK-I was negative in 95% of the liver 
metastases. The HNK-I antigen may playa role in the organ specific metastatic behavior of 
uveal melanomas. In Chapter 11 we propose a model for progression in uveal melanoma, 
based on cell type or tumor diameter. 
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Samenvatting 
Het doel van dit onderzoek was het identificeren van betrouwbare progressie parameters als 
prognostisch merkteken in het primaire melanoom van de uvea, vooral gericht op klinisch-
pathologische parameters. Aigemene achtergrondinformatie over de epidemiologie, de 
histologische cJassificatie, de tumor gradering, de overleving en de therapie wordt gegeven 
in Hoofdstuk 2. De moeilijkheden bij het reproduceren van de subjectieve histologische 
classificatie hebben geleid tot onderzoek naar meer objectieve parameters. Uit onze 
naspeuringen naar de voortgang in het onderzoek over nieuwe prognostische parameters 
blijkt dat op het gebied van de cytomorfometrie (de diameter van de tien grootste nucleoli 
en de standaard deviatie van het nllcleolus oppervlak) en DNA analyse (ploidie studies) 
niellwe parameters werden gevonden. Recente klinisch-pathologische onderzoeken wezen 
op het belang van de tumor vasculatllllr (de aanwezigheid van gesloten vaatpatronen) als 
een van de prognostische factoren, welke het meest significant bleek in het voorspellen van 
het metastaserend gedrag van het uveamelanoom. Bij het vergelijken van de relevante 
literatuur op het gebied van de cytogenetica blijkt dat er op dit ge!>ied aanzienlijke 
verschillen zijn met het huidmelanoom. Verder zijn er verschillen aangetoond in het 
phenotype van melanoom-geassocieerde antigenen. Tot heden is er weinig onderzoek 
verricht op het gebied van cel-cel en cel-matrix interacties. Hierbij werden echter ook ook 
verschillen gevonden tussen het huidmelanoom en het uveamelanoom. Hieruit kan 
geconcludeerd worden dat deze verschillen waarschijnlijk gerelateerd zijn aan het verschi! 
in biologisch gedrag tussen deze tumoren. 
Progressie in tumoren kan gedefinieerd worden als voortdurende toename in graad van 
kwaadaardigheid. Het is moeilijk om benigne of voorloperlesies van het uveamelanoom te 
verkrijgen. In Hoofdstuk 4 beschrijven wij een zeldzaam geval van -paraneoplastische-
bilaterale, melanocytaire hyperplasie waaruit een bilateraaillvea melanoom is ontstaan. Uit 
ons onderzoek op het gebied van het genotype van het uveanlelanoom is gebleken dat er 
geen puntmutaties in het N-ras gen konden worden aangetoond (Hoofdstuk 5). Deze 
mutaties zijn echter wei gevonden in het huidmclanoom en werden toegeschreven aan het 
effect van ultraviolet straling. In een serie hllidmelanomen werd de -als Ki-67 
gedefinieerde- proliferatie activiteit bepaald door middel van immllnohistochemie 
(hoofdstuk 6). We vergeleken melanomen, welke voorafgaande aan de enucleatie werden 
bestraald, met niet-voorbestraalde tllmoren. Uit onze bevindingen blijkt dat niet-
voorbestraalde tumoren cen significant hogere proliferatie activiteit hadden. Een associatie 
met klinisch-pathologische parameters kon niet worden aangetoond. Om het opvallende 
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verschi! in aneuploidie, beschreven voor het uveamelanoom te onderzoeken, hebben we 
DNA flow cytometrie verricht (Hoofdstuk 7). Wij vonden een sterke correlatie tussen 
DNA-ploidie en het ce!type, maar niet met andere klinisch-pathologische parameters. 
Verder vonden wij in voorbestraalde melanomen significant meer aneuploidie dan in niet-
voorbestraalde melanomen. De DNA-ploidie en de tumordiameter waren factoren welke het 
meest significant waren als parameter voor de overleving. We hebben retrospectief 
proliferatie-markers zoals de mitosenfrequentie en de Mib-I (Ki-67) index in een serie 
uveamelanomen onderzocht en de prognostische waarde hiervan vergeleken met klinisch-
pathologische parameters. In dezelfde studie onderzochten wij de expressie van de 
regulerende eiwitten c-myc en Bcl-2 (Hoofdstuk 8). Het bleek dat cytoplasmatische 
expressie van het c-myc oncoproteine en de Mib-I index bruikbaar zijn als onafllankelijke 
prognostische parameters. De sterk omgekeerde correlatie tussen c-myc en Bcl-2 expressie 
duidt op een samenwerking tussen c-myc en Bcl-2 waardoor melanoomcellen in leven 
blijven. Degradatie van de extracellulaire matrix en andere weefselbarrieres is noodzakelijk 
voor het verwerven van metastaseringscapacileit. Een belangrijk proteolytisch systeem, dat 
betrokken is bij tumor progressie, omvat de eiwilten van het plasminogeen activator (PA) 
systeem. We onderzochten de expressie en de verschillende componenten van het PA 
systeem en de aanwezigheid van PA enzymactivileil (Hoofdstuk 9). We hebben aangetoond 
dat urokinase-PA expressie correleert met het optreden van metastasen, hoewel de 
prognostische waarde van urokinase-PA nog moet worden bepaald. Tissue-type PA was 
opvallend aanwezig aan het front van tumorinvasie (richting sclera en de membraan van 
Bruch). De verschillende componenten van het PA systeem kwamen aanzienlijk minder tot 
expressie dan bij het huidmelanoom. In Hoofdstuk 10 hebben wij de rol onderzocht van 
neurale cel adhesie moleculen (NCAM) in het ontwikkelen van metastaseringscapacileit in 
een serie primaire en gemetastaseerde uveamelanomen. Wij vonden dat NCAM en in 
mindere mate HNK-I geassocieerd zijn met het ontwikkelen van metastaseringscapaciteit. 
Er werd geen overeenkomst gevonden tllssen de expressie van NCAM en HNK-I in de 
primaire tumoreo en hun corresponderende metastasen. Dit houdt in dat expressie van deze 
ceiadhesiemoieclilen geen essentieel karakteristiek is van de tllmorcellen, maar 
waarschijnlijk beinvloed wordt door de micro-omgeving. Het HNK-I antigeen was negatief 
in 95 % van de lever metastasen. Het HNK-I antigeen kan daarom een rol spelen in het 
orgaanspecifieke metastaseringsgedrag van uveamelanomen. In Hoofdstuk II stellen wij 
een progressie model op voor het lIveamelanoom, gebaseerd op het ceHype en de tumor 
diameter. 
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